Oxymetazoline is a synthetic imidazoline derivative that acts as a potent alpha-adrenergic agonist. It is primarily used as a topical nasal decongestant, effectively shrinking swollen nasal membranes and relieving congestion. Its synthesis involves a multi-step process, starting with the reaction of 2-imidazoline with an appropriate aldehyde. Oxymetazoline's effects are primarily due to its ability to stimulate alpha-adrenergic receptors in the nasal mucosa, resulting in vasoconstriction and reduced blood flow. Its importance lies in its effectiveness in treating nasal congestion associated with conditions like the common cold, sinusitis, and allergic rhinitis. It is studied to understand its pharmacokinetic properties, optimize its formulation for improved efficacy and safety, and explore its potential applications in other medical areas like ophthalmology.'
Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 4636 |
| CHEMBL ID | 762 |
| CHEBI ID | 7862 |
| SCHEMBL ID | 24301 |
| MeSH ID | M0015681 |
| Synonym |
|---|
| AC-6370 |
| AB00053513-12 |
| BRD-K16195444-001-01-7 |
| gtpl124 |
| DIVK1C_000567 |
| KBIO1_000567 |
| SPECTRUM_001051 |
| phenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- |
| einecs 216-079-1 |
| oxymetazolinum [inn-latin] |
| navisin |
| brn 0886303 |
| nezeril |
| oxymetazoline [inn:ban] |
| nafrine |
| operil |
| oximetazolina [inn-spanish] |
| vicks sinex |
| tocris-1142 |
| NCGC00022345-02 |
| NCGC00015766-02 |
| cas-151615 |
| NCGC00015766-01 |
| lopac-o-2378 |
| LOPAC0_000903 |
| PRESTWICK2_000224 |
| BIOMOL-NT_000161 |
| BSPBIO_000267 |
| BPBIO1_000295 |
| BPBIO1_000419 |
| SPECTRUM5_001114 |
| PRESTWICK3_000224 |
| phenol, 3-[(4,5-dihydro-1h-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- (9ci) |
| oxylazine |
| 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol |
| 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline |
| h 990 |
| 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol |
| sinerol |
| hsdb 3143 |
| 3-[(4,5-dihydro-1h-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol |
| phenol, 3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethyl- |
| phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- |
| rhinofrenol |
| iliadin |
| phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- (7ci,8ci) |
| oxymethazoline |
| phenol, 3-[(4,5-dihydro-1h-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- |
| oximetazolinum |
| rhinolitan |
| 3-(4,5-dihydro-1h-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol |
| hazol |
| 1491-59-4 |
| C07363 |
| oxymetazoline |
| afrin |
| oxymetozoline |
| DB00935 |
| BSPBIO_002145 |
| IDI1_000567 |
| NCGC00022345-06 |
| NCGC00022345-05 |
| KBIO2_004099 |
| KBIOSS_001531 |
| KBIO3_001645 |
| KBIO2_001531 |
| KBIOGR_000908 |
| KBIO2_006667 |
| SPECTRUM3_000533 |
| PRESTWICK0_000224 |
| SPBIO_001095 |
| SPBIO_002188 |
| SPECTRUM4_000464 |
| NINDS_000567 |
| PRESTWICK1_000224 |
| SPECTRUM2_000998 |
| NCGC00015766-03 |
| NCGC00022345-04 |
| 6-tert-butyl-3-(4,5-dihydro-1h-imidazol-2-ylmethyl)-2,4-dimethylphenol |
| HMS2089G03 |
| NCGC00015766-10 |
| CHEMBL762 |
| chebi:7862 , |
| nasacon |
| L000459 |
| operil (tn) |
| oxymetazoline (inn) |
| D08322 |
| NCGC00015766-08 |
| STK075254 |
| AKOS007930348 |
| oxymetazolinum |
| oximetazolina |
| unii-8vln5b44zy |
| 8vln5b44zy , |
| dtxsid3040691 , |
| dtxcid1020691 |
| tox21_110217 |
| cas-1491-59-4 |
| CCG-204985 |
| NCGC00015766-06 |
| NCGC00015766-11 |
| NCGC00015766-09 |
| NCGC00015766-07 |
| NCGC00015766-05 |
| NCGC00015766-04 |
| oxymetazoline hydrochloride crystalline |
| navasin |
| FT-0601532 |
| oxymetazoline [who-dd] |
| oxymetazoline [vandf] |
| oxymetazoline [hsdb] |
| oxymetazoline [inn] |
| oxymetazoline [mi] |
| SCHEMBL24301 |
| tox21_110217_1 |
| NCGC00015766-13 |
| AB00053513-13 |
| oxymetazolina |
| 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-phenol;hydrochloride |
| 6-tert-butyl-3-(4,5-dihydro-1h-imidazol-2-ylmethyl)-2,4-dimethyl-phenol;hydrochloride |
| bdbm30712 |
| cid_66259 |
| nasivine (salt/mix) |
| h-990 |
| 6-tert-butyl-3-(4,5-dihydro-1h-imidazol-2-ylmethyl)-2,4-dimethylphenol # |
| AB00053513_15 |
| AB00053513_14 |
| HY-12722 |
| SBI-0050878.P004 |
| NCGC00015766-16 |
| phenol,3-[(4,5-dihydro-1h-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- |
| 6-tert-butyl-3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-2,4-dimethylphenol |
| Q417813 |
| 6-(tert-butyl)-3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-2,4-dimethylphenol |
| BRD-K16195444-003-16-1 |
| SDCCGSBI-0050878.P005 |
| NCGC00015766-21 |
| EN300-23521946 |
| 6-tert-butyl-3-[(4,5-dihydro-1h-imidazol-2-yl)methyl]-2,4-dimethylphenol |
| CS-0012298 |
| oxymetazolinum (inn-latin) |
| a14aa05 |
| s01ga04 |
| r01aa05 |
| 3-((4,5-dihydro-1h-imidazol-2-yl)methyl)-6-(1,1-dimethylethyl)-2,4-dimethylphenol |
| oximetazolina (inn-spanish) |
| r01ab07 |
Oxymetazoline (OXZ) is a synthetic, highly selective agonist for alpha 1A-adrenoceptor. It is commonly used as a topical hemostatic agent in the operating room during ear, nose, and throat surgery.
Oxymetazoline has been used as decongesting nosedrops for more than 25 years. No objective dose-response study of the drug has been published. The drug has a 50-fold lower affinity for alpha1D ARs compared to alpha1A ARs.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Oxymetazoline has a 50-fold lower affinity for alpha1D ARs compared to alpha1A ARs and also displayed a significant loss of affinity for an alpha1A Leu-290 to Phe mutant." | ( Bulk is a determinant of oxymetazoline affinity for the alpha1A-adrenergic receptor. Gaivin, R; McCune, D; Perez, D; Rorabaugh, B, 2004) | 1.35 |
| "Oxymetazoline has a 50-fold lower affinity for alpha1D ARs compared to alpha1A ARs and also displayed a significant loss of affinity for an alpha1A Leu-290 to Phe mutant." | ( Bulk is a determinant of oxymetazoline affinity for the alpha1A-adrenergic receptor. Gaivin, R; McCune, D; Perez, D; Rorabaugh, B, 2004) | 1.35 |
| "Oxymetazoline has been used as decongesting nosedrops for more than 25 years but so far no objective dose-response study of the drug has been published. " | ( Nasal decongestant effect of oxymetazoline in the common cold: an objective dose-response study in 106 patients. Akerlund, A; Klint, T; Olén, L; Rundcrantz, H, 1989) | 2.01 |
Oxymetazoline did not cause ototoxicity in a chinchilla animal model 2 months after a single application via a tympanostomy tube. It has a 50-fold lower affinity for alpha1D ARs compared to alpha1A ARs and also displayed a significant loss of affinity for an alpha 1A Leu-290 to Phe mutant.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Oxymetazoline did not cause ototoxicity in a chinchilla animal model 2 months after a single application via a tympanostomy tube." | ( Oxymetazoline ototoxicity in a chinchilla animal model. Akache, F; Akinpelu, OV; Daniel, SJ; Funnell, WR; Sahmkow, S, 2012) | 3.26 |
| "Oxymetazoline has a 50-fold lower affinity for alpha1D ARs compared to alpha1A ARs and also displayed a significant loss of affinity for an alpha1A Leu-290 to Phe mutant." | ( Bulk is a determinant of oxymetazoline affinity for the alpha1A-adrenergic receptor. Gaivin, R; McCune, D; Perez, D; Rorabaugh, B, 2004) | 1.35 |
| "The oxymetazoline-evoked increase in urethral pressure was inhibited by WB-4101 with an ID50 (dose that gives half of the inhibitory effect) significantly lower than that for rauwolscine." | ( Selectivity of oxymetazoline for urethral pressure vs blood pressure in the anaesthetized female rabbit. Alberts, P; Fredrickson, MG; Gillberg, PG; Modiri, AR, 2000) | 1.14 |
Oxymetazoline treatment delayed the release of NA, the NA biological half-lives rising from 12 up to 36 hours in the heart and from 5.9 up to 21 hours in sub-maxillary glands. Treatment with oxymetazoline as adjunctive therapy with energy-based therapy was safe, well tolerated, and reduced facial erythema.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Oxymetazoline treatment delayed the release of NA, the NA biological half-lives rising from 12 up to 36 hours in the heart and from 5.9 up to 21 hours in sub-maxillary glands." | ( Effect of the activation of alpha-adrenoreceptors on the synthesis and release of noradrenaline by peripheral adrenergic nerves in vivo. Beley, A; Bralet, J; Rochette, L, 1976) | 0.98 |
| "oxymetazoline, and pretreatment with the vasopressin antagonist, d(CH2)5Tyr(Me)AVP, significantly attenuated it." | ( Stimulation of central alpha-2 adrenoceptors inhibits gastric secretion in rats by releasing vasopressin. Puurunen, J, 1988) | 1 |
| "Treatment with oxymetazoline as adjunctive therapy with energy-based therapy was safe, well tolerated, and reduced facial erythema in patients with moderate to severe persistent facial erythema associated with rosacea. " | ( Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study. Alvandi, N; Bai, Z; Dover, JS; Geronemus, RG; Goldberg, DJ; Shanler, SD; Tanghetti, EA, 2021) | 2.42 |
| "The treatment with oxymetazoline with preservative, oxymetazoline without preservative and xylometazoline with preservative was evaluated." | ( [Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis]. Dorn, M; Hofmann, W; Knick, E, 2003) | 0.92 |
Oxymetazoline nasal spray, mupirocin ointment, and clotrimazole cream are safe and effective as off-label medications for tympanostomy tube care in children. However, our analysis of specific adverse events found that the oxymetzoline group was only significantly higher than the vehicle group in the incidence of application-site dermatitis.
Oxymetazoline concentrations from the two-times-MRD administration were approximately 50 percent greater than those from the MRD administration. Pharmacokinetic analyses were conducted in patients receiving oxymetzoline.
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the first study (study 1), oxymetazoline administered with a bellows (OXBE) was compared both with a placebo belows (PLBE) as well as with oxymetazoline and placebo administered with a conventional nasal spray (OXSP respective PLSP) in 73 patients." | ( The efficacy of oxymetazoline administered with a nasal bellows container and combined with oral phenoxymethyl-penicillin in the treatment of acute maxillary sinusitis. Berglund, R; Stierna, P; Tönnesson, M; Westrin, KM; Wiklund, L, 1994) | 0.92 |
| "To observe and analyze the effect of compound shuanghua tablets combined with western medicine on serum and secretion inflammatory factors in patients with acute secretory otitis media caused by swimming." | ( Compound shuanghua tablets combined with Western medicine on serum and secretion inflammatory factors in patients with acute secretory otitis media caused by swimming. Zhang, W, 2018) | 0.48 |
Oxymetazoline nasal products might not be a safety concern because of the typical low-dose and brief dosage regimen limited to nasal delivery. In the absence of morphine the inhibitory effects of the presynaptic alpha-adrenoceptor agonists were much reduced and the dose-response curve was flat. To date, there have not been adequate pediatric pharmacokinetic studies of oxymetzoline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "4 X 10(-6) M) produced parallel shifts to the right of the dose-response curves to noradrenaline and oxymetazoline in isolated strips of cat splenic capsule." | ( The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen. Blakeley, AG; Summers, RJ, 1977) | 0.47 |
| " 2 In the absence of morphine the inhibitory effects of the presynaptic alpha-adrenoceptor agonists, clonidine and oxymetazoline were much reduced and the dose-response curve was flat." | ( The inhibitory effects of presynaptic alpha-adrenoceptor agonists on contractions of guinea-pig ileum and mouse vas deferens in the morphine-dependent and withdrawn states produced in vitro. Gillan, MG; Kosterlitz, HW; Robson, LE; Waterfield, AA, 1979) | 0.47 |
| " Cocaine (2 x 10(-6) M and 10(-5) M) produced 2 and 7 fold shifts to the left of the dose-response curve to (-)-noradrenaline recorded isotonically in isolated splenic capsular strips of the cat." | ( Investigation of the role of calcium in the supersensitivity produced by cocaine in cat spleen strips. Summers, RJ; Tillman, J, 1979) | 0.26 |
| " Dose-response curves to the imidazoline, oxymetazoline, in the presence and absence of maximally stimulating concentrations of norepinephrine, indicated that oxymetazoline caused a dose-dependent inhibition of norepinephrine-stimulated hydrolysis of phosphoinositide." | ( Differences in imidazoline and phenylethylamine alpha-adrenergic agonists: comparison of binding affinity and phosphoinositide response. Crews, FT; Raulli, RE, 1991) | 0.55 |
| "Oxymetazoline has been used as decongesting nosedrops for more than 25 years but so far no objective dose-response study of the drug has been published." | ( Nasal decongestant effect of oxymetazoline in the common cold: an objective dose-response study in 106 patients. Akerlund, A; Klint, T; Olén, L; Rundcrantz, H, 1989) | 2.01 |
| " The dose-response curves generated by the model for partial agonists were similar to the curves obtained experimentally in vitro." | ( Relationship between alpha-adrenoceptor occupancy and contractile response in rat vas deferens. Experimental and theoretical analysis. Díaz-Toledo, A; Martí, MC, 1988) | 0.27 |
| " Ninety-eight ferrets were used in these experiments, which were undertaken to evaluate the efficacy of steroids and/or a long-acting vasoconstrictor, to develop dose-response curves for dexamethasone sodium phosphate if it proved efficacious, and to evaluate the possible synergistic effects of combination therapy." | ( Use of steroids and a long-acting vasoconstrictor in the treatment of postintubation croup. A ferret model. Pillsbury, HC; Postma, DS; Prazma, J; Sidman, J; Woods, CI, 1987) | 0.27 |
| "3 alpha-Adrenoceptors appear to be involved in the reaction, since noradrenaline showed stereospecificity, and the alpha-adrenoceptor antagonists phentolamine and piperoxan both shifted the dose-response curves of the alpha-adrenoceptor agonist drugs to the right, usually parallel to the control curves." | ( Studies on the antinociceptive action of alpha-agonist drugs and their interactions with opioid mechanisms. Bentley, GA; Newton, SH; Starr, J, 1983) | 0.27 |
| " The assay permitted the analysis of nine samples per hour with the requisite sensitivity and selectivity and was used to determine the blood pharmacokinetics of oxymetazoline in rats dosed via intravenous and intranasal routes." | ( Rapid liquid chromatographic-mass spectrometric assay for oxymetazoline in whole rat blood. Baker, TR; Dobson, RL; Hayes, FJ; Tsueda, MS, 1995) | 0.73 |
| " The dose-response curve was of an inverted U shape since with 10 micrograms of oxymetazoline the plasma GH did not rise." | ( Hypothalamic alpha 2A-adrenoceptors stimulate growth hormone release in the rat. Kiem, DT; Makara, GB; Vizi, ES, 1995) | 0.52 |
| "10 ml in each puff with a dosage used in clinical practice." | ( Effects of topical nasal decongestants on histology of nasal respiratory mucosa in rabbits. Chon, KM; Hong, SH; Jeong, CH; Min, YG; Suh, SH, 1995) | 0.29 |
| " On days 1, 2, 3, and 7, NAR and VAS measurements were obtained before the morning dose and up to 6 hours after dosing; clinical visual examinations were also performed before dosing on these days." | ( An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion. Eccles, R; Martez, SJ; Morris, S; Riker, DK; Witek, TJ, ) | 0.36 |
| " Dose-response data show dexmedetomidine to be the most potent inhibitor." | ( Inhibition of water permeability in the rat collecting duct: effect of imidazoline and alpha-2 compounds. Hébert, CA; Kudo, LH; Rouch, AJ, 1999) | 0.3 |
| "To evaluate the dose-response relationship of increasing doses of oxymetazoline compared with placebo in normal subjects, and to determine the sensitivities of rhinomanometry, acoustic rhinometry and symptoms in discriminating between differing doses of oxymetazoline in normal subjects." | ( Evaluation of the dose-response relationship for intra-nasal oxymetazoline hydrochloride in normal adults. Bickford, L; Shakib, S; Taverner, D; Tonkin, A, 1999) | 0.78 |
| "The study had a randomized, double-blind, placebo-controlled, parallel group, dose-response design." | ( Evaluation of the dose-response relationship for intra-nasal oxymetazoline hydrochloride in normal adults. Bickford, L; Shakib, S; Taverner, D; Tonkin, A, 1999) | 0.54 |
| "tVOL shows a clear dose-response relationship for the range of doses of oxymetazoline administered." | ( Evaluation of the dose-response relationship for intra-nasal oxymetazoline hydrochloride in normal adults. Bickford, L; Shakib, S; Taverner, D; Tonkin, A, 1999) | 0.78 |
| " In the first 3 h after administration of PPA, there was a dose-response increase in the systolic and diastolic blood pressures, which then returned to baseline." | ( Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects. Graf, P; Hallén, H; Palm, J; Toll, K, 1999) | 0.3 |
| " Sympathomimetic dosage and type, time interval until stroke onset, and neuroimaging findings are described." | ( Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Arauz, A; Barinagarrementeria, F; Cantu, C; López, M; Murillo-Bonilla, LM, 2003) | 0.32 |
| " Bioadhesive nasal inserts have a high potential as new nasal dosage form for extended drug delivery." | ( In situ gelling, bioadhesive nasal inserts for extended drug delivery: in vitro characterization of a new nasal dosage form. Bertram, U; Bodmeier, R, 2006) | 0.33 |
| " At higher concentrations, 3 x 10(-5) and 10(-4) m, of the antagonist, the agonist dose-response curve was shifted to the right with a decrease in the maximum effect." | ( Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum. Miller, DD; Patil, PN; Salazar-Bookaman, MM, 2006) | 0.33 |
| "Outcomes evaluated were peak nasal inspiratory flow, nasal resistance, blood flow, and oxymetazoline dose-response curve (DRC)." | ( Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Clearie, K; Khan, F; Lipworth, B; Vaidyanathan, S; Williamson, P, 2010) | 0.9 |
| " Nevertheless, we conclude that the formation of this reactive species might not be a safety concern for oxymetazoline nasal products because of the typical low-dose and brief dosage regimen limited to nasal delivery." | ( In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Daniels, JS; Gan, LS; LeDuc, BW; Mahajan, MK; Uttamsingh, V; Williams, DA, 2011) | 0.89 |
| " A dose-response curve was constructed using doubling doses of oxymetazoline of 25 μg, 50 μg, 100 μg, and 200 μg at 20 minute intervals." | ( Comparative evaluation of nasal blood flow and airflow in the decongestant response to oxymetazoline. Lipworth, B; Vaidyanathan, S; Williamson, P, 2012) | 0.84 |
| " High resolution MRI scans of the nasal turbinates were obtained immediately prior to dosing (baseline) and at approximately 1, 8, 10, 11, and 12 h after dosing." | ( Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging. Brum, J; Glover, M; Gowland, P; Guthrie, G; Hull, D; Kappler, G; Pritchard, S; Ramsey, D; Stuart, S; Thomas, P, 2014) | 0.71 |
| " Plasma samples for pharmacokinetic assessments were collected prior to dosing and 6 times postdose on days 1 and 28." | ( Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. Ahluwalia, G; Attar, M; DuBois, J; Kuang, AW, 2018) | 0.77 |
| "This phase 2 study evaluated the optimal oxymetazoline dosing regimen in patients with moderate to severe persistent facial erythema of rosacea." | ( Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea. Ahluwalia, G; Berk, DR; Dover, JS; DuBois, J; Jones, TM; Weiss, RA, 2018) | 1.01 |
| "0% QD provided the optimal dosing regimen and was selected for evaluation in phase 3 clinical studies." | ( Phase 2 Randomized, Dose-Ranging Study of Oxymetazoline Cream for Treatment of Persistent Facial Erythema Associated With Rosacea. Ahluwalia, G; Berk, DR; Dover, JS; DuBois, J; Jones, TM; Weiss, RA, 2018) | 0.75 |
| " To date, there have not been adequate pediatric pharmacokinetic studies of oxymetazoline, so caution should be exercised with both the quantity of dosing and the technique of administration." | ( Topical Nasal Decongestant Oxymetazoline: Safety Considerations for Perioperative Pediatric Use. Cartabuke, R; Jatana, KR; Tobias, JD, 2021) | 1.15 |
| " Data on safety and safe dosage are limited." | ( Safety of topical administration of nasal decongestants and vasoconstrictors in paediatric nasal surgery - A systematic review. Edafe, O; Macmillan, AJ; Phoon, KM, 2022) | 0.72 |
| " There is scope for further studies to establish safe dosage in the paediatric population given the paucity of current literature." | ( Safety of topical administration of nasal decongestants and vasoconstrictors in paediatric nasal surgery - A systematic review. Edafe, O; Macmillan, AJ; Phoon, KM, 2022) | 0.72 |
| "These real-world data on Oxymetazoline cream 1% in rosacea-associated erythema may help making clinic decision and informing treatment expectations, and more clinic trials on longer-term dosing or the combination treatment with oral medication and energy-based therapy are worth exploring." | ( Benefits and safety of Oxymetazoline cream 1% on rosacea-associated erythema: A systematic review and analysis of clinical evidence. Yin, D; Yuan, X, 2023) | 1.52 |
| Role | Description |
|---|---|
| alpha-adrenergic agonist | An agent that selectively binds to and activates alpha-adrenergic receptors. |
| sympathomimetic agent | A drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. |
| nasal decongestant | A drug used to relieve nasal congestion in the upper respiratory tract. |
| vasoconstrictor agent | Drug used to cause constriction of the blood vessels. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| carboxamidine | Compounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom. |
| imidazolines | Diazoline compounds having the nitrogen atoms at the 1- and 3-positions and a double bond at an unspecified position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 61.1936 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 11.8832 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| GLS protein | Homo sapiens (human) | Potency | 1.4125 | 0.3548 | 7.9355 | 39.8107 | AID624146 |
| TDP1 protein | Homo sapiens (human) | Potency | 20.9763 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 4.7308 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 35.7168 | 0.0013 | 18.0743 | 39.8107 | AID926 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 34.1854 | 0.0013 | 10.1577 | 42.8575 | AID1259252; AID1259253; AID1259255; AID1259256 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 1.9497 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 35.4813 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.6834 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 5.5367 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 6.3096 | 0.0025 | 5.8400 | 31.6228 | AID899 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 15.8489 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 9.1064 | 0.0010 | 6.0009 | 35.4813 | AID943; AID944 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.3981 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| chaperonin GroEL | Methanococcus maripaludis S2 | Potency | 100.0000 | 31.6228 | 31.6228 | 31.6228 | AID488978 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Ataxin-2 | Homo sapiens (human) | Potency | 12.5893 | 0.0119 | 12.2221 | 68.7989 | AID588378 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 0.5780 | 0.0001 | 1.0076 | 8.7800 | AID625218 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.3030 | 0.0000 | 0.8871 | 10.0000 | AID625218 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 (µMol) | 3.2610 | 0.0000 | 1.1546 | 7.5858 | AID625154 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.4550 | 0.0000 | 0.7951 | 9.1201 | AID625154 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 (µMol) | 1.3320 | 0.0001 | 0.9917 | 8.0000 | AID625155 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.9570 | 0.0000 | 0.7292 | 6.9183 | AID625155 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 0.0230 | 0.0000 | 1.4421 | 7.3470 | AID625201 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.0890 | 0.0001 | 0.8074 | 10.0000 | AID1063789; AID35785; AID36039; AID36071; AID36180; AID36204; AID36205; AID36206; AID36208; AID36209; AID36210; AID36211; AID36212; AID36325; AID36497; AID36514; AID625201 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 (µMol) | 0.2000 | 0.0000 | 2.0151 | 10.0000 | AID625249 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 1.2730 | 0.0000 | 1.2380 | 8.1590 | AID625202 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.4101 | 0.0002 | 0.7257 | 10.0000 | AID35785; AID36039; AID36180; AID36204; AID36205; AID36206; AID36208; AID36209; AID36210; AID36211; AID36212; AID36236; AID36325; AID36497; AID36514; AID625202 |
| Alpha-1A adrenergic receptor | Bos taurus (cattle) | Ki | 0.0132 | 0.0000 | 0.5072 | 3.7020 | AID36463 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 2.6330 | 0.0000 | 1.4725 | 7.8980 | AID625203 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.1090 | 0.0003 | 0.4834 | 10.0000 | AID1063788; AID35785; AID36039; AID36180; AID36204; AID36205; AID36206; AID36208; AID36209; AID36210; AID36211; AID36212; AID36325; AID36497; AID36514; AID36533; AID625203 |
| Alpha-1B adrenergic receptor | Mesocricetus auratus (golden hamster) | Ki | 0.2042 | 0.0000 | 2.0167 | 9.6000 | AID37185 |
| Alpha-2A adrenergic receptor | Sus scrofa (pig) | Ki | 0.0210 | 0.0044 | 1.3751 | 4.1000 | AID36501 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0056 | 0.0003 | 1.3833 | 8.4000 | AID625190 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 0.0001 | 0.7396 | 10.0000 | AID625190 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.2002 | 0.0000 | 0.9296 | 10.0000 | AID1353524; AID36362; AID37220; AID37221; AID37222; AID37223; AID37224; AID37226; AID37228; AID37229; AID37230; AID37359 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.2073 | 0.0000 | 0.9708 | 10.0000 | AID1353524; AID37220; AID37221; AID37222; AID37223; AID37224; AID37226; AID37228; AID37229; AID37230; AID37359 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.2073 | 0.0000 | 0.9375 | 10.0000 | AID1353524; AID37220; AID37221; AID37222; AID37223; AID37224; AID37226; AID37228; AID37229; AID37230; AID37359 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3311 | 0.0000 | 0.5751 | 10.0000 | AID35739 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 2.8440 | 0.0002 | 0.7568 | 8.8970 | AID625200 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.9297 | 0.0000 | 0.3609 | 10.0000 | AID35463; AID36325; AID625200 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Ki | 0.0004 | 0.0001 | 0.8087 | 10.0000 | AID4618 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 0.0003 | 0.0001 | 0.5485 | 9.2100 | AID4249 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 (µMol) | 1.2850 | 0.0001 | 0.8801 | 8.8500 | AID625192 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.3670 | 0.0000 | 0.3855 | 10.0000 | AID625192 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 (µMol) | 0.5780 | 0.0001 | 1.0302 | 9.0000 | AID625218 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.3030 | 0.0001 | 0.9549 | 10.0000 | AID625218 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0056 | 0.0005 | 1.4835 | 7.8000 | AID625190 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 0.0003 | 1.2967 | 9.2440 | AID625190 |
| Alpha-2B adrenergic receptor | Mus musculus (house mouse) | Ki | 0.0913 | 0.0002 | 0.1091 | 2.1500 | AID36361; AID36362; AID36363 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.1297 | 0.0000 | 0.2726 | 10.0000 | AID35739; AID36136; AID36325 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.3593 | 0.0000 | 0.4713 | 10.0000 | AID36325; AID37185; AID37359 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 (µMol) | 3.0560 | 0.0001 | 1.1873 | 8.9125 | AID625217 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 1.9450 | 0.0003 | 0.7693 | 10.0000 | AID625217 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3311 | 0.0000 | 0.9650 | 10.0000 | AID35739 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 (µMol) | 1.6700 | 0.0017 | 0.8381 | 5.4200 | AID625221 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.7750 | 0.0002 | 0.5229 | 10.0000 | AID625221 |
| Alpha-2C adrenergic receptor | Mus musculus (house mouse) | Ki | 0.0913 | 0.0002 | 0.1091 | 2.1500 | AID36361; AID36362; AID36363 |
| Alpha-2A adrenergic receptor | Mus musculus (house mouse) | Ki | 0.0913 | 0.0002 | 0.1091 | 2.1500 | AID36361; AID36362; AID36363 |
| Alpha-2A adrenergic receptor | Bos taurus (cattle) | Ki | 0.0015 | 0.0015 | 0.1019 | 0.2200 | AID35908 |
| Nischarin | Homo sapiens (human) | Ki | 0.0062 | 0.0042 | 0.2192 | 3.8019 | AID342861 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | EC50 (µMol) | 0.0033 | 0.0008 | 0.3733 | 6.7100 | AID35956 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | EC50 (µMol) | 12.5694 | 0.0054 | 3.2510 | 20.9400 | AID36629; AID37346 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 25.1189 | 0.0270 | 0.8793 | 3.0000 | AID37346 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 25.1189 | 0.0270 | 0.9709 | 3.0000 | AID37346 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 25.1189 | 0.0270 | 0.9709 | 3.0000 | AID37346 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | EC50 (µMol) | 11.7142 | 0.0015 | 1.7227 | 5.6000 | AID32972; AID35447; AID35453 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | EC50 (µMol) | 0.0200 | 0.0126 | 0.0379 | 0.0631 | AID36629 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | EC50 (µMol) | 0.0200 | 0.0013 | 0.0388 | 0.0970 | AID36629 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | EC50 (µMol) | 0.0200 | 0.0126 | 0.0319 | 0.0631 | AID36629 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | EC50 (µMol) | 0.0201 | 0.0001 | 0.5098 | 7.1000 | AID32967; AID36133; AID36629 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | EC50 (µMol) | 11.7142 | 0.0001 | 1.3010 | 5.6000 | AID32970; AID37346; AID37350 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID35450 | Agonist potency at alpha 2c adrenoceptors assayed in CHO cells expressing human Alpha-1D adrenergic receptor; ND is No Data. | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID1216586 | Drug metabolism in NADPH supplemented rabbit liver microsomes fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-tert-butyl-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216551 | Retention time of the compound at 50 uM by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216611 | Activity of human recombinant CYP1A2 assessed as glutathione conjugate formation at 50 uM in presence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37224 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in rat RNG clone | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID503832 | Partial agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as effect on kinetics of receptor conformational change by FRET assay | 2005 | Nature chemical biology, Jun, Volume: 1, Issue:1 | Molecular basis of inverse agonism in a G protein-coupled receptor. |
| AID35463 | Affinity to human Alpha-1D adrenergic receptor determined by radioligand binding techniques from rat-1 fibroblasts membranes | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID1216585 | Drug metabolism in NADPH supplemented rabbit liver microsomes fraction assessed as 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37044 | Binding affinity towards Alpha-1A adrenergic receptor in rat submaxillary glands | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID37036 | In vitro agonist potency towards Alpha-1A adrenergic receptor in rat vas deferens | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID1216565 | Drug metabolism in NADPH non-supplemented rabbit liver S9 fraction treated with 50 uM oxymetazoline assessed as compound-N-acetyl cysteine conjugate formation in presence of N-acetyl cysteine by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36039 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in canine adipocytes | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID1216564 | Drug level in NADPH supplemented rabbit liver S9 fraction treated with 50 uM oxymetazoline assessed as compound-N-acetyl cysteine conjugate formation in presence of N-acetyl cysteine by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37221 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in neonatal rat lung | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID36205 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in human OK cells | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID35908 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in bovine pineal | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID4288 | Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1216598 | Activity of human recombinant CYP2C19 assessed as 3-((1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216608 | Activity of human recombinant CYP2E1 assessed as metabolite formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216575 | Drug metabolism in NADPH supplemented rabbit liver S9 fraction assessed as 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM in presence of glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216571 | Drug metabolism in NADPH supplemented rat liver S9 fraction assessed as 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM in presence of glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36133 | Agonist potency at Alpha-1 adrenergic receptor assayed in rat-1 fibroblasts expressing human Alpha-1 adrenergic receptor | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID180025 | Percent response towards alpha 1A adrenergic receptor in rat vas deferens using phenylephrine as control agonist | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID342861 | Displacement of [125I]PIC from human imidazoline receptor 1 in human platelets analyzed under norepinephrine mask of alpha 2AR | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | QSAR study of imidazoline antihypertensive drugs. |
| AID1216581 | Activity of human recombinant CYP2C18 assessed as glutathione conjugate formation at 50 uM in presence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36180 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in hamster adipocytes | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID37222 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in rat RG10 clone | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID1063789 | Displacement of [125I]Clonidine from adrenergic alpha2A receptor (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds. |
| AID32970 | Potency against cloned human alpha 1B adrenoceptor expressed in rat-1 fibroblasts. | 2001 | Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21 | 2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides. |
| AID32967 | Agonist potency against cloned human alpha 1A adrenoceptor expressed in rat-1 fibroblasts. | 2001 | Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21 | 2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides. |
| AID227718 | Binding energy by using the equation deltaG obsd = -RT ln KD | 1984 | Journal of medicinal chemistry, Dec, Volume: 27, Issue:12 | Functional group contributions to drug-receptor interactions. |
| AID60508 | Percent response towards alpha 1A adrenergic receptor in canine prostate using phenylephrine as control agonist | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID1216568 | Activity of human recombinant CYP2C19 assessed as 3-((1H-imidazol-2-yl)methyl)-6-tert-butyl-2,4-dimethylphenol formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID234297 | Selectivity is the ratio of binding affinities of alpha 1A adrenergic receptor to alpha 1b adrenergic receptor | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID36629 | In vitro activation of human alpha-1A receptor expressed in rat-1 fibroblasts via calcium mobilization through the Gq coupled PLC pathway as functional assay | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | 2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series. |
| AID1216610 | Activity of human recombinant CYP3A4 assessed as metabolite formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37223 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in rat RG20 clone | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID36212 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in human platelets | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID1216603 | Activity of human recombinant CYP1A2 assessed as metabolite formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216588 | Drug metabolism in NADPH supplemented rat liver microsomes fraction assessed as 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216606 | Activity of human recombinant CYP2C9 assessed as metabolite formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216614 | Activity of human recombinant CYP2C9 assessed as glutathione conjugate formation at 50 uM in presence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216583 | Activity of human recombinant CYP2D6 assessed as glutathione conjugate formation at 50 uM in presence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36514 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in rabbit adipocytes | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID1137409 | Displacement of [3H]clonidine from alpha-adrenergic receptor in rat brain | 1979 | Journal of medicinal chemistry, Nov, Volume: 22, Issue:11 | Ultraviolet photoelectron spectroscopy of cyclic amidines. 1. Electronic structure of some alpha-adrenergic benzylimidazolines. |
| AID35785 | Binding affinity towards Alpha-2 adrenergic receptor | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1216597 | Drug metabolism in NADPH supplemented human liver S9 fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM in presence of glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36533 | Affinity to human Alpha-2C adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID35160 | In vitro agonist potency towards Alpha-1B adrenergic receptor in rat spleen | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID1216569 | Drug metabolism in NADPH supplemented rat liver S9 fraction assessed as (S)-2-amino-5-((R)-3-(5-tert-butyl-2-((4,5-dihydro-1H-imidazol-2-yl)methyl)-4-hydroxy-3-methylbenzylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoic acid formation a | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID234298 | Selectivity is the ratio of binding affinities of alpha 1A adrenergic receptor to alpha 1d adrenergic receptor | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID1216600 | Activity of human recombinant CYP2C19 assessed as (S)-2-amino-5-((R)-3-(5-tert-butyl-2-((4,5-dihydro-1H-imidazol-2-yl)methyl)-4-hydroxy-3-methylbenzylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoic acid formation at 50 uM in presence of | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216582 | Activity of human recombinant CYP2E1 assessed as glutathione conjugate formation at 50 uM in presence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID35186 | The ability to displace [3H]clonidine from the Alpha-2 adrenergic receptor was determined in rat brain membrane | 1982 | Journal of medicinal chemistry, Dec, Volume: 25, Issue:12 | alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. |
| AID36501 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in porcine alpha2-clone | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID4618 | Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1216602 | Activity of human recombinant CYP2C19 assessed as glutathione conjugate formation at 50 uM in absence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216592 | Drug metabolism in NADPH supplemented human liver microsomes fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-tert-butyl-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37230 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in rat submaxillaries | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID37346 | Agonist potency at Alpha-1B adrenergic receptor expressed in rat-1 fibroblasts | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID1216554 | Drug recovery in NADPH supplemented rabbit liver S9 fraction treated with 50 uM oxymetazoline assessed as compound level after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216593 | Drug metabolism in NADPH supplemented human liver microsomes fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36470 | In vitro agonist potency towards Alpha-1A adrenergic receptor in canine prostate | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID36130 | Efficacy as % of the maximal effect observed for nonselective agonist phenylephrine in rat-1 fibroblasts expressing human Alpha-1 adrenergic receptor | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID1216579 | Drug metabolism in NADPH supplemented rat liver S9 fraction assessed as metabolite formation at 50 uM by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216580 | Drug metabolism in NADPH supplemented human liver S9 fraction assessed as metabolite formation at 50 uM by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1353524 | Displacement of [3H]-clonidine from alpha2-adrenergic receptor in rat brain cortex after 30 mins by Microbeta scintillation counting method | 2018 | European journal of medicinal chemistry, Mar-10, Volume: 147 | Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT |
| AID1216576 | Drug metabolism in NADPH supplemented rabbit liver S9 fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM in presence of glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216584 | Activity of human recombinant CYP3A4 assessed as glutathione conjugate formation at 50 uM in presence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36211 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in human alpha2C4 clone | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID36362 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in mouse Malpha2-4H | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID342863 | Selectivity ratio of pKi for human imidazoline receptor 1 to pKi for human alpha2 adrenoceptors | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | QSAR study of imidazoline antihypertensive drugs. |
| AID233040 | Binding Selectivity was determined [Selectivity = Ki against h5-HT1B receptor / Ki against h5-HT1D receptor] | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1216567 | Activity of human recombinant CYP2C19 assessed as 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36522 | Efficacy as percentage of the maximal effect observed for nonselective agonist UK-14304 in CHO cells expressing human Alpha-2C adrenergic receptor; ND is No Data. | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID4662 | Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID36325 | Binding affinity towards Alpha-1 adrenergic receptor | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1216577 | Drug metabolism in NADPH supplemented rabbit liver S9 fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-tert-butyl-2,4-dimethylphenol formation at 50 uM in presence of N-acetyl cysteine by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37185 | Binding affinity towards hamster clonal Alpha-1B adrenergic receptor | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID1216591 | Drug metabolism in NADPH supplemented human liver microsomes fraction assessed as 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID763645 | Displacement of [3H]-RX821002 from alpha2 adrenoreceptor in rat brain cortical membranes after 45 mins by competition assay in presence of GTP | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. |
| AID311932 | Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM | 2008 | Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2 | Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. |
| AID36204 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in human HT-29 cells | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID35956 | Agonist potency at Alpha-2A stably expressed in CHO cells. | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID35447 | Agonist potency at Alpha-1D adrenergic receptor assayed in rat-1 fibroblasts expressing human Alpha-1D adrenergic receptor | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID35739 | Binding affinity towards rat clonal Alpha-1D adrenergic receptor | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID4520 | Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV) | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID36497 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in opossum kidney | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID1216574 | Drug metabolism in NADPH supplemented rabbit liver S9 fraction assessed as (S)-5-((R)-3-(2-((1H-imidazol-2-yl)methyl)-5-tert-butyl-4-hydroxy-3-methylbenzylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-2-amino-5-oxopentanoic acid formation at 50 uM i | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID4287 | Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID36463 | Binding affinity towards bovine clonal Alpha-1A adrenergic receptor | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID180026 | Percent response towards alpha 1B adrenergic receptor in rat spleen using phenylephrine as control agonist | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID1216607 | Activity of human recombinant CYP2C18 assessed as metabolite formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID35453 | In vitro activation of human alpha-1D receptor expressed in rat-1 fibroblasts via calcium using mobilization through the Gq coupled PLC pathway as functional assay | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | 2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series. |
| AID36363 | Compound was evaluated for inhibition of binding of [3H]-MK-91 to Alpha-2 adrenergic receptor in mouse NG-108 cells | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID35954 | Efficacy as percentage of the maximal effect observed for nonselective agonist UK-14304 in CHO cells expressing human Alpha-2A adrenergic receptor | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID1216590 | Drug metabolism in NADPH supplemented rat liver microsomes fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216613 | Activity of human recombinant CYP2C8 assessed as glutathione conjugate formation at 50 uM in presence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID180028 | Percent response towards alpha 1D adrenergic receptor in rat aorta using phenylephrine as control agonist | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID1216609 | Activity of human recombinant CYP2D6 assessed as metabolite formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID4663 | Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1216604 | Activity of human recombinant CYP2B6 assessed as metabolite formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID32966 | Efficacy against alpha 1A adrenoceptor in human expressed as phenylephrine response at the dose of 40 uM | 2001 | Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21 | 2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides. |
| AID36206 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in human Y-79 cells | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID1216578 | Drug metabolism in NADPH supplemented rabbit liver S9 fraction assessed as metabolite formation at 50 uM by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37343 | Efficacy as % of the maximal effect observed for nonselective agonist phenylephrine in rat-1 fibroblasts expressing human Alpha-1B adrenergic receptor; ND is No Data | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID1216594 | Drug metabolism in NADPH supplemented human liver S9 fraction assessed as (S)-2-amino-5-((R)-3-(5-tert-butyl-2-((4,5-dihydro-1H-imidazol-2-yl)methyl)-4-hydroxy-3-methylbenzylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoic acid formation | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1063788 | Displacement of [125I]Clonidine from adrenergic alpha2C receptor (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds. |
| AID37229 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in rat kidney | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID1216573 | Drug metabolism in NADPH supplemented rabbit liver S9 fraction assessed as (S)-2-amino-5-((R)-3-(5-tert-butyl-2-((4,5-dihydro-1H-imidazol-2-yl)methyl)-4-hydroxy-3-methylbenzylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-5-oxopentanoic acid formatio | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36410 | Agonist potency at Alpha-2C adrenergic receptor assayed in CHO cells expressing human Alpha-2C adrenergic receptor; Nd is No Data. | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID32972 | Potency against cloned human alpha 1D-adrenoceptor expressed in rat-1 fibroblasts. | 2001 | Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21 | 2-(Anilinomethyl)imidazolines as alpha(1)-adrenoceptor agonists: the identification of alpha(1A) subtype selective 2'-carboxylic acid esters and amides. |
| AID36210 | Compound was evaluated for inhibition of binding of [3H]-MK-91 to Alpha-2 adrenergic receptor in human alpha-2C2 clone | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID36361 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in mouse Malpha2-10H clone | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID1216570 | Drug metabolism in NADPH supplemented rat liver S9 fraction assessed as (S)-5-((R)-3-(2-((1H-imidazol-2-yl)methyl)-5-tert-butyl-4-hydroxy-3-methylbenzylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-2-amino-5-oxopentanoic acid formation at 50 uM in p | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37228 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in rat enterocytes | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID23715 | Apparent partion coefficient of compound was evaluated in octanol/buffer at pH of 7.4 at 37 degree Centigrade | 1984 | Journal of medicinal chemistry, Apr, Volume: 27, Issue:4 | Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists. |
| AID1216595 | Drug metabolism in NADPH supplemented human liver S9 fraction assessed as (S)-5-((R)-3-(2-((1H-imidazol-2-yl)methyl)-5-tert-butyl-4-hydroxy-3-methylbenzylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-2-amino-5-oxopentanoic acid formation at 50 uM in | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36783 | 50% inhibition of specific [3H]clonidine binding (0.4 nM) to Alpha-2 adrenergic receptors in rat isolated brain membranes | 1984 | Journal of medicinal chemistry, Apr, Volume: 27, Issue:4 | Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists. |
| AID1216572 | Drug metabolism in NADPH supplemented rat liver S9 fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM in presence of glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216587 | Drug metabolism in NADPH supplemented rabbit liver microsomes fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36236 | Affinity to human Alpha-2B adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID1216553 | Drug recovery in NADPH supplemented rat liver S9 fraction treated with 50 uM oxymetazoline assessed as compound level after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37359 | Affinity to human Alpha-1B adrenergic receptor determined by radioligand binding techniques from rat-1 fibroblasts membranes | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID36071 | Affinity to human Alpha-2A adrenergic receptor determined by radioligand binding techniques from chinese hamster ovary (CHO) cells | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID37226 | Inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in rat adipocytes | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID36715 | Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.4 nM) to rat isolated brain membranes by 50% was reported. | 1984 | Journal of medicinal chemistry, Apr, Volume: 27, Issue:4 | Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists. |
| AID37350 | In vitro activation of human Alpha-1B receptor expressed in rat-1 fibroblasts via calcium mobilization through the Gq coupled PLC pathway as functional assay | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | 2-(anilinomethyl)imidazolines as alpha1A adrenergic receptor agonists: 2'-heteroaryl and 2'-oxime ether series. |
| AID1216596 | Drug metabolism in NADPH supplemented human liver S9 fraction assessed as 3-((4,5-dihydro-1H-imidazol-2-yl)methyl)-6-(1-hydroxy-2-methylpropan-2-yl)-2,4-dimethylphenol formation at 50 uM in presence of glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID4249 | Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1216552 | Drug recovery in NADPH supplemented human liver S9 fraction treated with 50 uM oxymetazoline assessed as compound level after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1216612 | Activity of human recombinant CYP2B6 assessed as glutathione conjugate formation at 50 uM in presence of NADPH and glutathione by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID1137408 | Binding affinity to alpha-adrenergic receptor in rabbit jejunum | 1979 | Journal of medicinal chemistry, Nov, Volume: 22, Issue:11 | Ultraviolet photoelectron spectroscopy of cyclic amidines. 1. Electronic structure of some alpha-adrenergic benzylimidazolines. |
| AID1216589 | Drug metabolism in NADPH supplemented rat liver microsomes fraction assessed as 3-((1H-imidazol-2-yl)methyl)-6-tert-butyl-2,4-dimethylphenol formation at 50 uM after 1 hr by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36136 | Affinity to Alpha-1 adrenergic receptor determined by radioligand binding techniques from rat-1 fibroblasts membranes | 2002 | Journal of medicinal chemistry, May-23, Volume: 45, Issue:11 | 2-(Anilinomethyl)imidazolines as alpha1 adrenergic receptor agonists: the discovery of alpha1a subtype selective 2'-alkylsulfonyl-substituted analogues. |
| AID1216601 | Activity of human recombinant CYP2C19 assessed as (S)-5-((R)-3-(2-((1H-imidazol-2-yl)methyl)-5-tert-butyl-4-hydroxy-3-methylbenzylthio)-1-(carboxymethylamino)-1-oxopropan-2-ylamino)-2-amino-5-oxopentanoic acid formation at 50 uM in presence of NADPH and g | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID36208 | Compound was evaluated for inhibition of binding of [3H]-MK-91 to Alpha-2 adrenergic receptor in human adipocytes | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID35618 | In vitro agonist potency towards Alpha-1D adrenergic receptor in rat aorta | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Synthesis and in vitro characterization of N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl]methanesulfonamide and its enantiomers: a novel selective alpha 1A receptor agonist. |
| AID36209 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in human alpha2C10 clone | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID197169 | Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats. | 1984 | Journal of medicinal chemistry, Apr, Volume: 27, Issue:4 | Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists. |
| AID1216605 | Activity of human recombinant CYP2C8 assessed as metabolite formation at 50 uM in presence of NADPH by LC-MS/MS method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 39, Issue:4 | In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. |
| AID37220 | Compound was evaluated for inhibition of binding of [3H]MK-91 to Alpha-2 adrenergic receptor in RIN-m5F cells | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. |
| AID342860 | Displacement of [125I]PIC from human alpha2 adrenoceptors expressed in CHO cells | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | QSAR study of imidazoline antihypertensive drugs. |
| AID1345908 | Human alpha1A-adrenoceptor (Adrenoceptors) | 1999 | British journal of pharmacology, Jun, Volume: 127, Issue:4 | Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells. |
| AID1345920 | Rat alpha1D-adrenoceptor (Adrenoceptors) | 1994 | Molecular pharmacology, Nov, Volume: 46, Issue:5 | Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. |
| AID1346049 | Human alpha2A-adrenoceptor (Adrenoceptors) | 1994 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3 | The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. |
| AID1345908 | Human alpha1A-adrenoceptor (Adrenoceptors) | 1995 | Molecular pharmacology, Aug, Volume: 48, Issue:2 | KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. |
| AID1346000 | Human alpha1B-adrenoceptor (Adrenoceptors) | 1995 | European journal of pharmacology, Nov-30, Volume: 291, Issue:3 | NS-49, a novel alpha 1a-adrenoceptor-selective agonist characterization using recombinant human alpha 1-adrenoceptors. |
| AID1346049 | Human alpha2A-adrenoceptor (Adrenoceptors) | 1998 | Biochemical pharmacology, Apr-01, Volume: 55, Issue:7 | Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. |
| AID624216 | Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C | 1999 | Journal of neurochemistry, May, Volume: 72, Issue:5 | High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. |
| AID1346058 | Human alpha2B-adrenoceptor (Adrenoceptors) | 1998 | Biochemical pharmacology, Apr-01, Volume: 55, Issue:7 | Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. |
| AID1345971 | Human alpha1D-adrenoceptor (Adrenoceptors) | 1995 | European journal of pharmacology, Nov-30, Volume: 291, Issue:3 | NS-49, a novel alpha 1a-adrenoceptor-selective agonist characterization using recombinant human alpha 1-adrenoceptors. |
| AID1346000 | Human alpha1B-adrenoceptor (Adrenoceptors) | 1995 | Molecular pharmacology, Aug, Volume: 48, Issue:2 | KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. |
| AID1346159 | Human alpha2C-adrenoceptor (Adrenoceptors) | 1998 | Biochemical pharmacology, Apr-01, Volume: 55, Issue:7 | Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. |
| AID1346528 | Human 5-HT1D receptor (5-Hydroxytryptamine receptors) | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1346893 | Human 5-HT2C receptor (5-Hydroxytryptamine receptors) | 1999 | Journal of neurochemistry, May, Volume: 72, Issue:5 | High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. |
| AID1345908 | Human alpha1A-adrenoceptor (Adrenoceptors) | 1995 | European journal of pharmacology, Nov-30, Volume: 291, Issue:3 | NS-49, a novel alpha 1a-adrenoceptor-selective agonist characterization using recombinant human alpha 1-adrenoceptors. |
| AID1345908 | Human alpha1A-adrenoceptor (Adrenoceptors) | 1995 | British journal of pharmacology, Sep, Volume: 116, Issue:1 | Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1-adrenoceptor subtypes. |
| AID1346159 | Human alpha2C-adrenoceptor (Adrenoceptors) | 1994 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3 | The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. |
| AID1345971 | Human alpha1D-adrenoceptor (Adrenoceptors) | 1995 | Molecular pharmacology, Aug, Volume: 48, Issue:2 | KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. |
| AID1346058 | Human alpha2B-adrenoceptor (Adrenoceptors) | 1994 | The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3 | The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. |
| AID1346049 | Human alpha2A-adrenoceptor (Adrenoceptors) | 1997 | Trends in pharmacological sciences, Jun, Volume: 18, Issue:6 | Gene targeting--homing in on alpha 2-adrenoceptor-subtype function. |
| AID1346264 | Human 5-HT1B receptor (5-Hydroxytryptamine receptors) | 1998 | Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13 | Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 211 (30.71) | 18.7374 |
| 1990's | 201 (29.26) | 18.2507 |
| 2000's | 108 (15.72) | 29.6817 |
| 2010's | 116 (16.89) | 24.3611 |
| 2020's | 51 (7.42) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (67.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 128 (17.34%) | 5.53% |
| Reviews | 25 (3.39%) | 6.00% |
| Case Studies | 41 (5.56%) | 4.05% |
| Observational | 1 (0.14%) | 0.25% |
| Other | 543 (73.58%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylephrine Versus Tranexamic Acid to Control Bleeding in Patients Undergoing Inferior Turbinoplasty by Coblation [NCT05841251] | 80 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | |||
| Characterization of the Effects on Bioimpedance and the Sensorimotor System After the Application of Percutaneous Electrolysis Protocols on the Patellar Tendon. [NCT05390359] | 50 participants (Actual) | Interventional | 2022-11-01 | Completed | |||
| A Single-dose, Randomized, Crossover Bioequivalence Study to Compare Two Formulations of Paracetamol/Phenylephrine [NCT01112462] | Phase 1 | 40 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Comparison of the Hemodynamic Effects of Phenylephrine and Norepinephrine in Patients Undergoing Deep Inferior Epigastric Perforator (DIEP) Flap Surgery. [NCT03872570] | Phase 4 | 40 participants (Anticipated) | Interventional | 2019-06-01 | Recruiting | ||
| ED90 of Norepinephrine and Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive Treatment During Cesarean Section [NCT06158048] | 80 participants (Anticipated) | Interventional | 2025-01-01 | Not yet recruiting | |||
| ED90 of Norepinephrine and Phenylephrine Boluses for Treating Postspinal Anesthesia Hypotension Under Intensive Treatment in Preeclamptic Patients During Cesarean Section [NCT06158035] | 80 participants (Anticipated) | Interventional | 2025-07-01 | Not yet recruiting | |||
| ED90 of Norepinephrine and Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive Treatment in Preeclamptic Patients During Cesarean Section [NCT06158022] | 80 participants (Anticipated) | Interventional | 2025-01-01 | Not yet recruiting | |||
| ED90 of Norepinephrine and Phenylephrine Boluses for Treating Postspinal Anesthesia Hypotension Under Intensive Treatment During Cesarean Section [NCT06158009] | 80 participants (Anticipated) | Interventional | 2025-04-01 | Not yet recruiting | |||
| Novel Role of Acetylcholine in Regulating Vascular Tone: Effects of Age and Exercise Training [NCT03972683] | Early Phase 1 | 0 participants (Actual) | Interventional | 2019-04-16 | Withdrawn(stopped due to no participants enrolled) | ||
| Preoperative Cataract Pupillary Dilation: Inpatient vs Outpatient [NCT01169688] | 50 participants (Actual) | Interventional | 2007-12-31 | Completed | |||
| A Multi-Center, Double-Masked, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil [NCT03751098] | Phase 3 | 76 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| Comparison of Continuous Infusion of Noradrenaline Versus Phenylephrine During Cesarean Section Under Spinal Anesthesia. A Randomized Controlled Trial [NCT03842046] | 82 participants (Actual) | Interventional | 2019-02-16 | Completed | |||
| Simultaneous Quantification of Dynamic and Static Cerebral Autoregulation (CA) at Different Steady-state Mean Blood Pressures Under Anaesthesia. [NCT03816072] | 66 participants (Actual) | Interventional | 2019-01-07 | Completed | |||
| Cardiovascular Changes and Tetracaine Pharmacokinetics Following Intranasal Administration of Standard and High Doses of Kovacaine Mist (Tetracaine Hydrochloride With Oxymetazoline Hydrochloride) in Healthy Volunteers [NCT01304316] | Phase 2 | 12 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Pilot Study to Evaluate Vbeam® Prima Pulsed Dye Laser (PDL) Treatment and RHOFADE® (Oxymetazoline HCL, 1% Cream) for Erythematotelangiectatic Rosacea [NCT04153188] | Phase 4 | 34 participants (Actual) | Interventional | 2019-01-15 | Completed | ||
| Randomized Double-blinded Comparison of Norepinephrine and Phenylephrine in Bolus for Maintenance of Blood Pressure During Spinal Anesthesia for Cesarean Delivery [NCT03702400] | Phase 2 | 72 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Neuro-Ox 2018: Assessment of Cerebral Oxygenation Under Three Clinically Relevant Conditions [NCT03682198] | 18 participants (Actual) | Interventional | 2018-09-24 | Completed | |||
| The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction [NCT03680404] | Phase 1 | 24 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| A Phase I Safety Study of Phenylephrine Applied Topically to the Oral Mucosa in Cancer Patients Receiving Radiation to Sub-mandibular Lymph Nodes [NCT01092975] | Phase 1 | 1 participants (Actual) | Interventional | 2010-03-31 | Terminated(stopped due to formulation/dose changes; planned changes to safety monitoring/reporting) | ||
| Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea [NCT03380390] | Phase 4 | 46 participants (Actual) | Interventional | 2017-12-04 | Completed | ||
| Long Pulse Versus Short Pulse Laser Dusting for Renal Stones [NCT03608098] | 0 participants (Actual) | Interventional | 2019-05-31 | Withdrawn(stopped due to Key study team members working on the study are leaving the institution.) | |||
| Combined Subconjunctival Atropine and Intracameral Epinephrine Injection for Pupil Dilation in Phacoemulsification Under Peribulbar Anesthesia. [NCT03638726] | Phase 4 | 40 participants (Anticipated) | Interventional | 2018-09-28 | Recruiting | ||
| Open Label, 2-Way Crossover Study to Assess the PK of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride on the PK of Intranasal Ketorolac Tromethamine in Healthy Male Subjects [NCT01363089] | Phase 1 | 21 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study [NCT04053478] | 144 participants (Anticipated) | Interventional | 2019-07-08 | Recruiting | |||
| [NCT02340910] | 46 participants (Anticipated) | Interventional | 2015-02-02 | Completed | |||
| Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure [NCT01333891] | 1 participants (Actual) | Interventional | 2012-12-31 | Terminated | |||
| Pretreatment With Topical Anesthesia or Decongestant for Reducing Pain and Discomfort During Fiberoptic Nasal Pharyngoscopy and Laryngoscopy: A Double Blind Randomized Study [NCT03620513] | Phase 4 | 160 participants (Actual) | Interventional | 2018-09-01 | Completed | ||
| The Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery and From the Nasal Mucosa During Operative Dentistry [NCT02062996] | Phase 2 | 0 participants (Actual) | Interventional | 2014-06-30 | Withdrawn(stopped due to Could not receive FDA approval for IND) | ||
| Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension [NCT02245230] | Phase 1 | 34 participants (Anticipated) | Interventional | 2015-01-31 | Active, not recruiting | ||
| The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects [NCT03139708] | Phase 1 | 5 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Feasibility of Tourniquet Use During Cement Fixation Only for TKR Surgery [NCT01162720] | 65 participants (Actual) | Interventional | 2008-11-30 | Terminated(stopped due to The risk of donor blood transfusion was unacceptably high in the Short Duration Group) | |||
| Randomized, Double-blind, Controlled Clinical Trial for Comparison of Continuous Phenylephrine Versus Norepinephrine Infusion for Maintenance of Hemodynamic Stability During Cesarean Section Under Spinal Anesthesia [NCT03849508] | Phase 4 | 124 participants (Actual) | Interventional | 2019-02-27 | Completed | ||
| Influence of a Bolus Administration of Ephedrine and Phenylephrine on the Spinal Oxygen Saturation, Measured With NIRS. [NCT03767296] | Phase 4 | 33 participants (Actual) | Interventional | 2017-02-06 | Completed | ||
| Sex Differences in Sympathetic Vascular Reactivity at High Altitude [NCT05525416] | 17 participants (Actual) | Interventional | 2022-07-28 | Completed | |||
| Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation [NCT02201121] | 94 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Phase 1, Randomized, Double-Blind, Placebo-Controlled, 4-Period, Complete Cross-Over Comparison of the Anesthetic Efficacy of Bilateral and Unilateral Application of Kovacaine Mist in Healthy Volunteers [NCT02457806] | Phase 1 | 48 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| The Effect of Epinephrine, Norepinephrine and Phenylephrine on Intraoperative Hemodynamic Performance - a Prospective Double-blinded Randomized Clinical Trial [NCT05492968] | Phase 4 | 225 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | ||
| 7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children: a Randomized Controlled Trial [NCT03221504] | 221 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | |||
| A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients [NCT02299557] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Preventive Intramuscular Phenylephrine in Elective Cesarean Section Under Spinal Anesthesia: A Randomized Controlled Tiral [NCT03507387] | 99 participants (Actual) | Interventional | 2018-04-01 | Completed | |||
| Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension [NCT05439460] | Phase 4 | 15 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| The Effects of Different High-intensity Interval Training Training Protocols on Cardiorespiratory Parameters in Patients With Type 2 Diabetes [NCT03487029] | 36 participants (Actual) | Interventional | 2018-03-02 | Completed | |||
| A Pilot Study to Evaluate the Effect of Changing Physiological Conditions on the Amplitude and/or Frequency of Myogenic Oscillations [NCT03719001] | Early Phase 1 | 40 participants (Actual) | Interventional | 2018-10-23 | Completed | ||
| Pulpal Blood Flow With the Use of Intra-nasal Anesthetic: a Randomized Double-blind Crossover Study [NCT03368391] | Phase 4 | 25 participants (Anticipated) | Interventional | 2018-01-03 | Not yet recruiting | ||
| Post-Traumatic Stress Disorder and Cardiovascular Disease Risk: Role of Sympathetic Overactivity and Angiotensin II [NCT02560805] | Phase 2 | 134 participants (Anticipated) | Interventional | 2015-10-31 | Suspended(stopped due to Enrollment and study activities are temporarily suspended due to COVID-19.) | ||
| Norepinephrine or Phenylephrine for Hypotension in Non-elective Cesarean Section [NCT04367103] | 180 participants (Actual) | Interventional | 2021-04-10 | Completed | |||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C [NCT00389896] | Phase 3 | 150 participants | Interventional | 2001-07-26 | Completed | ||
| A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems [NCT03098680] | Phase 1 | 18 participants (Actual) | Interventional | 2017-04-24 | Terminated(stopped due to Unable to recruit in time before end of PhD studentship) | ||
| Comparison of Prophylactic Norepinephrine and Phenylephrine Infusion for Hemodynamic Effects in Patients With Preeclampsia During Cesarean Section: a Randomized, Controlled Trial [NCT05035498] | 72 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold: a Prospective, Randomized, Double-blind, Controlled Trial [NCT05070650] | Phase 3 | 1,002 participants (Anticipated) | Interventional | 2024-09-20 | Not yet recruiting | ||
| Correlation and Effects on Cardiac Output With Intermittent Phenylephrine Administration of 50 mcg Versus 100 mcg or 100mcg/Min Prophylactic Infusion for Treatment of Hypotension in Parturients After Receiving Spinal Anesthesia for Cesarean Delivery [NCT02101047] | 0 participants (Actual) | Interventional | 2015-08-31 | Withdrawn(stopped due to lack of eligible participant) | |||
| A Randomized, Dose-ranging, Placebo-controlled Trial to Evaluate the Effects of Phenylephrine HCl Immediate Release Tablets on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis [NCT01330017] | Phase 2 | 539 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| The Effects of Nasal Airflow on Upper Airway Dilator Muscles During Sleep [NCT03506178] | 30 participants (Anticipated) | Interventional | 2017-09-12 | Recruiting | |||
| Evaluation of Costs and Consequences of Alternative Strategies of Intraoperative Fluid and Pharmacological Optimization. A Randomized Clinical Trial [NCT01141894] | 150 participants (Actual) | Interventional | 2010-03-31 | Terminated(stopped due to slow recruitment) | |||
| A Randomized Crossover Bioequivalence Study Comparing a Single Dose of Phenylephrine HCl 30 mg Extended Release Tablet to Three Phenylephrine HCl 10 mg Immediate Release Tablets Each Consecutively Dosed Four Hours Apart Under Fed and Fasting Conditions [NCT01354418] | Phase 1 | 24 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Randomized, Double-blind, Placebo-Controlled Study of the Efficacy of Phenylephrine HCL Extended-Release 30 mg and Phenylephrine HCL Immediate-Release 12 mg Capsules in Subjects With Nasal Congestion Due to the Common Cold [NCT03339726] | Phase 2 | 193 participants (Actual) | Interventional | 2017-11-30 | Terminated(stopped due to did not enroll enough subjects in the 2017/2018 cold season, so the study was terminated) | ||
| Phenylephrine Versus Ephedrine to Treat Spinal Anesthesia-Induced Hypotension in Preeclamptic Patients During Cesarean Delivery [NCT00458003] | 110 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial [NCT04623684] | Phase 4 | 25 participants (Actual) | Interventional | 2020-03-24 | Completed | ||
| A Double-Masked, Active-Controlled Study of the Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil [NCT03751631] | Phase 3 | 70 participants (Actual) | Interventional | 2018-11-15 | Completed | ||
| Phenylephrine Versus Norepinephrine in Septic Shock: Effects on Systemic and Regional Hemodynamics. A Randomized, Controlled, Trial [NCT00639015] | Phase 2 | 32 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Effect of Noradrenaline Infusuion Versus Phenyephrine Infusion in Improving Tissue Perfusion in HIPEC [NCT04144465] | 30 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| Efficacy and Tolerance of Ophthalmic Insert Mydriasert® Versus Reference Treatment (Phenylephrine and Tropicamide Eyedrops) in Premature Newborns, Neonates and Infants Justifying a Mydriasis for a Bilateral Diagnosis Fundus [NCT00642135] | Phase 3 | 80 participants (Actual) | Interventional | 2006-01-31 | Terminated(stopped due to The total number of patients has been reached.) | ||
| Intraoperative Phenylephrine Infusion to Reduce Postoperative Shivering in Lower Segment Caesarean Section [NCT04133961] | 118 participants (Actual) | Interventional | 2019-06-12 | Completed | |||
| Experimental Changes in Children's Sleep Duration and Timing: Effect on Obesity and Type 2 Diabetes Risk [NCT02979860] | 30 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| Norepinephrine Versus Phenylephrine Continuous Variable Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Double-blinded Trial [NCT03328533] | Phase 4 | 123 participants (Actual) | Interventional | 2017-11-10 | Completed | ||
| A Controlled Randomized, Open Label, Multicenter, Non-inferiority Trial Evaluating an Individualized Antibiotic Duration Treatment Based on Patient Clinical Response, Evaluated Through Connected Devices, for Community Acquired Pneumonia in the Community S [NCT04166110] | 310 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | |||
| Autoimmune Basis for Postural Tachycardia Syndrome [NCT02725060] | 58 participants (Anticipated) | Interventional | 2016-02-29 | Enrolling by invitation | |||
| Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Perc [NCT02099617] | Phase 4 | 1,200 participants (Actual) | Interventional | 2014-05-31 | Active, not recruiting | ||
| Comparison of the Potency of Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension in Patients With Severe Preeclampsia During Caesarean Section [NCT05035472] | 80 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Comparison of Different Protocols of Phenylephrine Infusion for Prophylaxis Against Post-spinal Hypotension During Cesarean Delivery [NCT03248817] | Phase 4 | 255 participants (Anticipated) | Interventional | 2017-09-28 | Recruiting | ||
| A Study Evaluating Pupil Dilation Speed With the Micro-Array Print (MAP) Dispenser Comparing 2 Dosing Regimens of Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution [NCT04907474] | Phase 4 | 60 participants (Actual) | Interventional | 2021-05-24 | Completed | ||
| Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study) [NCT04839224] | Phase 3 | 40 participants (Anticipated) | Interventional | 2021-04-05 | Recruiting | ||
| Sympathetic Nerve Activity and Vascular Function in Women With Uterine Leiomyomata [NCT02123069] | 28 participants (Actual) | Observational | 2013-04-30 | Completed | |||
| An Observational Study to Test the Effect of the Vasoactive Drugs Phenylephrine and Ephedrine on the Stroke Volume and Microvascular Blood Flow of Healthy Volunteers [NCT02252627] | 8 participants (Anticipated) | Observational | 2014-08-31 | Recruiting | |||
| Effects of Vasopressors on Cerebral Hemodynamics in Patients With Carotid Endarterectomy Under General Anesthesia(MRI Part): a Randomized Controlled Study [NCT05414877] | 60 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | |||
| A New More Efficient Cycloplegia Scheme [NCT02177539] | Phase 4 | 30 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Cerebral Hemodynamic and Metabolic Responses to Anesthesia and Vasopressors in Adult Surgery: A 2x2 Factorial Design Randomized Controlled Trial With Light-based Neuromonitoring (CHEM-FACT Study) [NCT05941494] | Phase 4 | 80 participants (Anticipated) | Interventional | 2023-10-03 | Recruiting | ||
| "A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product Oxymetazoline Hydrochloride Cream, 1% to Reference Product RHOFADETM Cream, 1% in the Trea [NCT03954444] | Phase 3 | 1,105 participants (Actual) | Interventional | 2019-04-15 | Completed | ||
| Up-down Determination of the ED90 of Phenylephrine for Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery [NCT00781157] | Phase 4 | 66 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans [NCT00806741] | 18 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia for Cesarean Section [NCT02854787] | Phase 4 | 120 participants (Anticipated) | Interventional | 2016-05-31 | Completed | ||
| Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth: A Randomized Clinical Trial [NCT04104789] | Phase 2 | 0 participants (Actual) | Interventional | 2020-09-30 | Withdrawn(stopped due to Manufacture of drug discontinued before any participants could be enrolled.) | ||
| Comparison of Norepinephrine and Phenylephrine in Cesarean Section by Transesophageal Ultrasound [NCT02759510] | Early Phase 1 | 106 participants (Anticipated) | Interventional | 2016-06-30 | Not yet recruiting | ||
| Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD [NCT02732756] | 69 participants (Actual) | Interventional | 2016-04-21 | Completed | |||
| The Effects of Different Vasopressors on the Innate Immune Response During Experimental Human Endotoxemia, a Pilot Proof-of-principle Study [NCT02675868] | Phase 4 | 40 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With Symptoms of an Upper Respir [NCT02678234] | Phase 3 | 0 participants (Actual) | Interventional | 2017-02-01 | Withdrawn(stopped due to The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.) | ||
| [NCT02802683] | Phase 4 | 72 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Comparison of Conventional Instillation and Lower Conjunctival Fornix Packing in Mydriasis for Premature Infants [NCT00877175] | Phase 4 | 25 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Evaluation of Ophthalmic Oxymetazoline as an Adjunct Treatment for Acquired Blepharoptosis Due to Periocular Synkinesis. [NCT05945615] | Phase 3 | 48 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide [NCT00356265] | 18 participants (Actual) | Interventional | 2006-07-31 | Terminated(stopped due to Futility: Impossible to recruit enough hypertensive participants to match Chronic Kidney Disease (CKD) participants on needed parameters.) | |||
| Effects of Vasopressors on Cerebral Hemodynamics in Patients With Carotid Endarterectomy Under General Anesthesia(TCD Part): a Randomized Controlled Study [NCT05665881] | 60 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| An Open-label Study to Assess the Effects of Allergic Rhinitis and Coadministration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine [NCT02154334] | Phase 1 | 47 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| A Phase 1 Study to Evaluate the Effects of Common Cold and of Concomitant Administration of Nasal Decongestant on the Pharmacokinetics and Pharmacodynamics of a Novel Glucagon Formulation in Otherwise Healthy Subjects [NCT02778100] | Phase 1 | 36 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Up-down Determination of the ED90 of the Initial Rate of Infusion of Phenylephrine for the Prophylaxis of Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery [NCT00796328] | Phase 4 | 45 participants (Actual) | Interventional | 2008-11-30 | Terminated(stopped due to Results Invalid, study closed, analysis cannot proceed.) | ||
| Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth: A Randomized Clinical Trial [NCT04105985] | Phase 2 | 0 participants (Actual) | Interventional | 2020-08-31 | Withdrawn(stopped due to Manufacturer discontinued drug before any participants could be enrolled.) | ||
| Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans [NCT00914394] | 12 participants (Actual) | Interventional | 2010-10-31 | Terminated | |||
| Comparison of the Effects of Norepinephrine and Phenylephrine on Tissue Oxygenation and Hemodynamic Stability During an Stroke Volume Variations(SVV) Fluid Guided Therapy in Elderly Undergoing Major Abdominal Surgery [NCT04067817] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-10-06 | Recruiting | ||
| A Randomized, Crossover, Double-Blind Study To Evaluate The Safety Of An Association Of Phenylephrine Hydrochloride 10mg + Acetaminophen 500mg + Dimethindene Maleate 1 Mg Compared To Phenylephrine Hydrochloride 10mg In Healthy Volunteers [NCT01026961] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2010-09-30 | Withdrawn(stopped due to Study is no longer required by Brazil health authority.) | ||
| Role of Angiotensin II in Insulin-induced Microvascular Activity [NCT01024543] | 18 participants (Actual) | Interventional | 2006-10-31 | Completed | |||
| Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors [NCT02713087] | Phase 4 | 48 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Effect of Phenylephrine Infusion for Preventing Hypotension During Shoulder Arthroscopic Surgery in the Beach Chair Position [NCT02585570] | 66 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Phenylephrine in Children and Adolescents [NCT00762567] | Phase 1 | 36 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Randomized, Two-Way Crossover, Multicenter, Consumer Preference Study of Two Oral Formulations of Phenylephrine Hydrochloride. [NCT00976209] | Phase 3 | 331 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Vasopressor Outcomes in Spine Surgery [NCT06053398] | 120 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | |||
| Exploration of Pupil Dilation in Horner's Patients Taking Flomax [NCT03615508] | Phase 4 | 1 participants (Actual) | Interventional | 2018-09-21 | Terminated(stopped due to incomplete enrollment) | ||
| Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation in Patients With Preeclampsia Under Spinal Anesthesia for Cesarean [NCT02245191] | 60 participants (Actual) | Interventional | 2014-07-31 | Active, not recruiting | |||
| Multicenter, Phase III, Randomized, Open, Parallel, Comparative to Evaluate the Efficacy and Safety of the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis and Allergic Reactions, in Pediatric Patients [NCT01393548] | Phase 3 | 879 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Phenylephrine Versus Upper Eyelid Taping For Muller's Muscle Conjunctival Resection Evaluation [NCT05890027] | Phase 4 | 30 participants (Anticipated) | Interventional | 2024-02-15 | Not yet recruiting | ||
| Use of the Hypotension Prediction Index Algorithm (HPI) for the Prevention of Intraoperative Hypotension (IOH) in Adult Patients Undergoing Spinal Surgery: Study Protocol for a Randomized Clinical Trial [NCT05341167] | 40 participants (Anticipated) | Interventional | 2022-06-06 | Recruiting | |||
| Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study [NCT01006863] | Phase 2 | 150 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Prophylactic Phenylephrine and Fluid Co-administration to Reduce Spinal Hypotension During Elective Caesarean Section in a Resource-limited Setting: a Prospective Alternating Intervention Study [NCT04005664] | 300 participants (Actual) | Interventional | 2018-05-01 | Completed | |||
| A Randomized Controlled Trial to Determine the Lowest Effective Dose for Adequate Mydriasis in Premature Infants [NCT01054027] | 15 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| Clinical Evaluation of Safety and Efficacy of Pediatric Naridrin in Comparison to Afrin on the Improval of Nasal Congestion. [NCT02601235] | Phase 3 | 292 participants (Actual) | Interventional | 2018-01-16 | Completed | ||
| The Dynamic Effects of Phenylephrine on Preload and Cardiac Output in Patients Under General Anaesthesia [NCT02739399] | Phase 4 | 26 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Combination Therapy With Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy Concomitant With Allergic Rhinitis [NCT02559440] | Phase 4 | 240 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Randomized Double Blind Trial of Vasoactive Drugs for the Management of Shock in the ICU [NCT02118467] | Phase 4 | 836 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Study to Determine the Best Regimen for Administration of Phenylephrine During Spinal Anesthesia for Cesarean Delivery, as Determined by Maternal Blood Pressure and Cardiac Output [NCT00996190] | Phase 4 | 60 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Comparative Analytical Study of Intravenous Bolus Dose of Mephentermine and Phenylephrine for Hemodynamic Stability During Elective Cesarean Section Under Spinal Anesthesia at KIST Medical College and Teaching Hospital [NCT05706727] | Phase 3 | 42 participants (Anticipated) | Interventional | 2023-03-23 | Recruiting | ||
| The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects [NCT03959176] | Phase 4 | 13 participants (Actual) | Interventional | 2019-07-20 | Completed | ||
| A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa [NCT00584987] | Phase 4 | 64 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Efficacy of Eccentric Resistance Training in Persons With Knee Osteoarthritis [NCT02350387] | 32 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Crossover Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber [NCT00276016] | Phase 3 | 39 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions [NCT05732701] | 2,788 participants (Anticipated) | Interventional | 2023-06-27 | Recruiting | |||
| Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring During Spinal Anaesthesia for Cesarean Section:A Prospective,Randomized, Controlled Study [NCT02532270] | 100 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | |||
| Induced Hypertension for Acute Ischemic Stroke [NCT00227448] | Phase 2 | 60 participants | Interventional | 2003-06-30 | Completed | ||
| Effect of Preventive Medicine on the Postreperfusion Syndrome [NCT01080625] | 96 participants (Actual) | Interventional | 2010-04-30 | Completed | |||
| Effect of Three Weight-adjusted Vasopressors for With Combined Spinal-Epidural Anesthesia for Elective Cesarean Delivery: A Randomized Controlled Trial [NCT04991662] | Phase 4 | 78 participants (Actual) | Interventional | 2021-10-10 | Completed | ||
| Short Term Effects of Long Duration Low Intensity Continuous Ultrasound for Trapezius Muscle Pain [NCT02135094] | 33 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia in Neurosurgical Patients [NCT06083948] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2023-12-20 | Recruiting | ||
| Stage 2, Double-blind, Randomized, Parallel Groups, One Centre Study in Patients With Allergic Rhinitis Treated With Nasal Oxymetazoline in Combination With Nasal Hydroxyl-propyl-methyl Cellulose (HPMC) or Placebo [NCT01986582] | Phase 2 | 40 participants (Anticipated) | Interventional | 2013-10-31 | Completed | ||
| Evaluation and Treatment of Autonomic Failure. [NCT00223691] | Phase 1 | 389 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| Effect of Phenylephrine or Dopamine Infusion on Cerebral Oxygen Saturation in Thoracic Surgery Patients [NCT02009007] | Phase 1 | 50 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| Comparsion of the Effect of High Versus Low Mean Arterial Pressure (MAP) Levels on Clinical Outcomes in Elderly Patients During Noncardiothoracic Surgery Under General Anesthesia [NCT02857153] | 322 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | |||
| Efficacy and Safety of Difluprednate Ophthalmic Emulsion vs. a Fixed-Combination of Prednisolone Acetate - Phenylephrine Ophthalmic Suspension on Post-operative Inflammation Following Cataract Surgery. [NCT04631315] | Phase 4 | 255 participants (Actual) | Interventional | 2019-03-24 | Completed | ||
| A Multicenter, Consumer Product Evaluation of a Single Dose of Phenylephrine Hydrochloride 30 mg Extended Release Tablets (Sinus Comfort™) [NCT04534452] | Phase 3 | 347 participants (Actual) | Interventional | 2012-05-12 | Completed | ||
| Comparison of the Effects of Phenylephrine and Norepinephrine on Hemodynamics and Tissue Oxygenation in Patients Undergoing Ophthalmic Surgery [NCT01609491] | 60 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Safety and Efficacy of Therapeutic Induced Hypertension in Patients With Acute Non-cardioembolic Ischemic Stroke: A Multicenter, Randomized, Open Label, Prospective, Phase 3 Study [NCT01600235] | Phase 3 | 170 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | ||
| Effect of Phenylephrine Infusion on Pulse Pressure Variability [NCT05011357] | Early Phase 1 | 6 participants (Anticipated) | Interventional | 2021-09-10 | Recruiting | ||
| A Pilot Study of the Effects of Nebulized Epoprostenol (Flolan) and Systemic Phenylephrine on Arterial Oxygenation During One Lung Ventilation [NCT02748265] | Phase 4 | 8 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Blood Pressure or Cardiac Output - the Influence on Cerebral Perfusion During Cardiopulmonary Bypass [NCT02806492] | 15 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Pheniramine Maleate 20 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With [NCT02730364] | Phase 3 | 0 participants (Actual) | Interventional | 2017-02-01 | Withdrawn(stopped due to The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.) | ||
| Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C [NCT02885168] | Phase 4 | 30 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Determinants of Optimal Benzodiazepines Withdrawal in Adults With Hypnotic-dependent Insomnia: a Randomised Controlled Trial Evaluating Acceptance and Commitment Therapy in Telepsychology [NCT04751851] | 128 participants (Anticipated) | Interventional | 2021-06-03 | Active, not recruiting | |||
| A Single-Center, Study Evaluating The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of Kovacaine Mist To Healthy Pediatric Subjects [NCT01952990] | Phase 2 | 18 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Acoustic Rhinometry: Impact of External Nasal Dilator on the Two First Notches of the Rhinogram [NCT01411969] | 16 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| A Double-blind, Randomised, Placebo-controlled Study to Evaluate Topical 10% Phenylephrine Gel in the Management of Ileal Pouch Anal Anastomosis (IPAA)-Related Faecal Incontinence [NCT00420797] | Phase 3 | 0 participants (Actual) | Interventional | 2007-02-28 | Withdrawn(stopped due to Terminated, new protocol to be developed) | ||
| Individually Tailored Elastic Compression Therapy After Deep Venous Thrombosis in Relation to the Incidence of Post Thrombotic Syndrome, a Randomized Multicenter Trial [NCT01429714] | 865 participants (Actual) | Interventional | 2011-03-22 | Completed | |||
| The Effects of ß1-receptor Blockade and α1-adrenergic Agonist on the Kinetics of Lactated Ringer's Solution During Surgery [NCT01431612] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Development of Advanced Double Intravenous Vasopressor Automated (ADIVA) System With Improved Hemodynamic Trend Control During Spinal Anaesthesia for Caesarean Section [NCT03620942] | 173 participants (Actual) | Interventional | 2018-11-07 | Active, not recruiting | |||
| A Comparison of Intermittent Intravenous Boluses of Phenylephrine and Norepinephrine to Prevent Spinal-induced Hypotension in Cesarean Deliveries: a Randomized Controlled Study [NCT02962986] | 112 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Randomized, Placebo-Controlled, Double-Blind, Two-Way Crossover Study to Evaluate the Effects of Phenylephrine HCl Extended-Release Tablets 30 mg Compared to Placebo on Ambulatory Blood Pressure [NCT00874120] | Phase 3 | 116 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| The Effect of Phenylephrine, Norepinephrine and Vasopressin on Cerebral Oxygentaion During Off Pump CABG: A Pilot Study [NCT04214145] | 90 participants (Actual) | Interventional | 2020-01-07 | Completed | |||
| The Effect of Capsaicin-Phenylephrine-Caffeine Formulation on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope [NCT04972123] | Phase 2 | 140 participants (Actual) | Interventional | 2021-07-20 | Completed | ||
| The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment [NCT00585091] | 15 participants (Actual) | Interventional | 2003-10-31 | Completed | |||
| A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction During Spinal Anesthesia for Cesarean Section and Its Relation to the Effect of Prophylaxis Phenylephrine [NCT02958215] | Phase 2 | 980 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| The Effect of Vibrissae on Subjective and Objective Measures of Nasal Obstruction [NCT01850511] | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability to Improve Perioperative Outcome During Spinal Anaesthesia for Caesarean Section [NCT02277730] | Phase 2/Phase 3 | 252 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Synergistic Use of Pilocarpine-Brimonidine-Oxymetazoline to Control Presbyopia Symptoms [NCT05006898] | Phase 1 | 11 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Evaluation of Light Sensitivity and Visual Acuity Changes as Consequence of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris [NCT04040790] | 10 participants (Actual) | Interventional | 2019-09-16 | Terminated(stopped due to Several reasons: Financing ended before all study assessments were performed, covid-19 delayed design, production and shipment of IMD, experience gained during the study made it clear that lens design should be changed) | |||
| Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth: A Randomized Clinical Trial [NCT03962634] | Phase 2 | 3 participants (Actual) | Interventional | 2019-08-28 | Terminated(stopped due to Drug is no longer being manufactured) | ||
| A Phase I/IIa Safety and Efficacy Study of Topical Phenylephrine Applied to Oral Mucosa in Bone Marrow Transplant Patients Receiving Cytoxan Plus Total Body Irradiation [NCT02434146] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2015-05-14 | Terminated(stopped due to A company in China has decided to license the product) | ||
| Sex Differences in Sympathetic Activity and Vascular Reactivity During Acute and Chronic Hypoxia. [NCT05001048] | 14 participants (Actual) | Interventional | 2019-08-04 | Completed | |||
| A Proof of Concept Study to Evaluate Differential Tachyphylaxis of Alpha 1 and Alpha 2 Adrenoreceptor Mediated Decongestant Response to Oxymetazoline and Its Acute Reversal by Corticosteroid in Healthy Volunteers [NCT00487032] | Phase 4 | 19 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Randomised, Double-blind, Phase IV Study to Compare the Incidence of ECG Changes During Elective Caesarean Section Under Spinal Anaesthesia When Using Phenylephrine or Ephedrine Infusion to Maintain Baseline Systolic Blood Pressure [NCT01243970] | Phase 4 | 29 participants (Actual) | Interventional | 2012-04-30 | Terminated(stopped due to Change in clinical practice since the start of the trial in 2011 (phenylephrine superior)) | ||
| 2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides [NCT00501878] | Phase 4 | 100 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Double-blind, Randomized, Placebo Controlled Study, Comparing Oxymetazoline 1% Cream TO RHOFADE in the Treatment of Moderate to Severe Persistent Facial Erythema Assocoated With Rosacea [NCT05148689] | Phase 1 | 82 participants (Actual) | Interventional | 2018-02-23 | Completed | ||
| Epinephrine Versus Phenylephrine Infusion for Prophylaxis Against Maternal Hypotension After Spinal Anesthesia for Cesarean Delivery: a Randomized Controlled Trial. [NCT05881915] | 196 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled Endpoint Selection and Questionnaire Validation Study to Assess the Niacin Induced Flushing Caused by NIASPAN (TM) [NCT00533676] | Phase 2 | 165 participants | Interventional | 2004-08-31 | Completed | ||
| A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0812 in Rheumatoid Arthritis Patients [NCT00542022] | Phase 2 | 149 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Hemodynamics and Extravascular Lung Water in Acute Lung Injury: A Prospective Randomized Controlled Multicentered Trial of Goal Directed Treatment of EVLW Versus Standard Management for the Treatment of Acute Lung Injury [NCT00624650] | Phase 2 | 33 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Comparison of Phenylephrine and Ephedrine in the Treatment of Hemodynamic Disorders After Spinal Anesthesia in the Elderly [NCT03858465] | 50 participants (Actual) | Interventional | 2019-02-01 | Completed | |||
| Variability in Adrenergic Response [NCT00838695] | 106 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| The Phenylephrine vs. Norepinephrine Infusion by Lidico Monitoring With Pregnancy Patients Undergoing Cesarean Section [NCT03833895] | Phase 2/Phase 3 | 238 participants (Actual) | Interventional | 2019-02-20 | Completed | ||
| Pilot Study On The Role Of Nitric Oxide In Alpha 1-Adrenergic Vasoreactivity [NCT00240058] | 22 participants (Actual) | Interventional | 2005-07-31 | Completed | |||
| Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation [NCT00120432] | Phase 3 | 80 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| The Effects of Height and Weight Adjusted Dose of Local Anesthetic Compared to Standard Dose for Spinal Anesthesia in Elective Cesarean Section [NCT02635555] | 160 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions [NCT00431392] | Phase 2 | 42 participants | Interventional | 2001-09-30 | Completed | ||
| Cardiovascular Hyporeactivity and Fatiguing Illness in Gulf War Veterans [NCT00100412] | 0 participants | Interventional | 1999-10-31 | Completed | |||
| PET Detection of the Effects of Aging on the Human Heart. Aim#1-Impact of Aging on Myocardial Remodeling: Role of Nitric Oxide [NCT00603720] | 54 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section [NCT01216410] | 306 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences [NCT05997732] | Phase 4 | 30 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| National Clinical Trial,Phase III, Multicenter, Randomized, Prospective, Double-blind, Parallel, Placebo-controlled, to Evaluate the Efficacy, Safety and Superiority of Decongex Gripe in the Treatment of Symptoms Associated With Common Cold [NCT02904304] | Phase 3 | 150 participants (Anticipated) | Interventional | 2020-12-31 | Suspended(stopped due to the viability of the study is being analyzed) | ||
| Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion [NCT00584662] | 42 participants (Actual) | Interventional | 2005-01-31 | Terminated | |||
| Exploring the Optimal Duration of a Group-based Online Behavioral Weight Loss Program [NCT04628533] | 0 participants (Actual) | Interventional | 2020-07-31 | Withdrawn(stopped due to COVID-19. Recruitment never began.) | |||
| Effects of Phenylephrine on Systemic and Regional Hemodynamics in Patients With Septic Shock: a Crossover Pilot Study [NCT00481442] | Phase 2 | 15 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery or Adenoidectomy [NCT02453841] | 30 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study [NCT04838665] | Phase 4 | 60 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Phase 2 Study Evaluating the Prophylactic Phenylephrine Infusion for Preventing Hypotension During Spinal Anesthesia for Lower Limb Orthopedic Surgery in the Elderly Patients [NCT01533662] | Phase 2 | 64 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea [NCT02095158] | Phase 3 | 440 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Mechanisms of Vasovagal Syncope [NCT01791816] | Early Phase 1 | 90 participants (Anticipated) | Interventional | 2013-02-28 | Active, not recruiting | ||
| Norepinephrine and Phenylephrine for Cesarean Section [NCT02969239] | Phase 4 | 50 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Comparison of Phenylephrine Infusion With Colloids vs. Crystalloids for Reduction of Spinal-induced Hypotension During Cesarean Section [NCT00846651] | Phase 4 | 82 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Proof of Concept Study to Evaluate if Concomitant Topical Intranasal Steroid Prevents Tolerance and Rebound Congestion Due to Regular Oxymetazoline in Persistent Allergic Rhinitis. [NCT00846326] | Phase 4 | 0 participants (Actual) | Interventional | Withdrawn(stopped due to The suppliers were unable to provide the investigational medicinal product (IMP)) | |||
| A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults [NCT01660893] | Phase 3 | 26 participants (Actual) | Interventional | 2012-08-31 | Terminated | ||
| [NCT00225043] | 60 participants (Actual) | Interventional | 2005-06-30 | Completed | |||
| Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant [NCT03590912] | Phase 4 | 160 participants (Actual) | Interventional | 2018-09-05 | Completed | ||
| Does Time From Ovulation Trigger To Oocyte Pick-Up Affect Intracytoplasmic Sperm Injection Outcomes? A Multi-Center Single-Blinded Randomized Controlled Trial Comparing 36 and 38 Hour Intervals [NCT05803655] | 850 participants (Anticipated) | Interventional | 2023-04-27 | Recruiting | |||
| Closed-loop Double-vasopressor Automated System vs Manual Bolus Vasopressor to Treat Hypotension During Spinal Anaesthesia for Caesarean Section [NCT04025918] | Phase 2/Phase 3 | 216 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients [NCT02701582] | 66 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Comparison of the Effects of Norepinephrine and Phenylephrine on Tissue Oxygenation and Hemodynamic Stability During an SVV Fluid Guided Therapy in Elderly Undergoing Radical Resection of Colon Cancer Surgery [NCT03215797] | Phase 3 | 40 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Comparison of Two Different Doses of Intramuscular Phenylephrine HCL for Prevention of Spinal Anesthesia Induced Hypotension During Cesarean Section: A Prospective Randomized Double-blinded Parallel Study [NCT05348980] | Phase 4 | 60 participants (Actual) | Interventional | 2020-01-01 | Completed | ||
| Seven Versus Fourteen Day Treatment for Male Urinary Tract Infection [NCT01994538] | 273 participants (Actual) | Interventional | 2014-04-24 | Completed | |||
| Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia [NCT02025426] | Phase 4 | 13 participants (Actual) | Interventional | 2012-09-30 | Terminated(stopped due to Significant challenges recruiting a difficult patient population with most surgeries occurring out of hours) | ||
| Antitussive Effect of a Naturally Flavored, Multi-Component Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo [NCT02062710] | Phase 4 | 22 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial. [NCT02285634] | 68 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| Camillian Saint Mary's Hospital Luodong [NCT05348148] | 450 participants (Anticipated) | Interventional | 2020-06-16 | Recruiting | |||
| Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia [NCT00199784] | Phase 4 | 80 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| [NCT01645774] | Phase 2/Phase 3 | 90 participants (Actual) | Interventional | 2011-01-31 | Terminated | ||
| Comparison of the Effects of Phenylephrine and Norepinephrine on Cardiac Function During Carotid Cross-Clamping During Carotid Endarterectomy Under General Anesthesia [NCT00294606] | 86 participants | Interventional | 2006-02-28 | Recruiting | |||
| A Non-randomized Experimental Study of Optically Registered Pharmacodynamic Responses During Iontophoresis of Vasoactive Substances to the Skin of Healthy Volunteers [NCT04777383] | 90 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | |||
| The Oxygenation of the Brain During Caesarean Section. A Comparison of Ephedrine Versus Phenylephrine [NCT01509521] | Phase 4 | 24 participants (Anticipated) | Interventional | 2012-02-29 | Completed | ||
| Open Label, Three-Way Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride and Multiple Doses of Fluticasone Propionate on the Absorption and Tolerab [NCT01365650] | Phase 1 | 24 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies [NCT01332578] | Phase 4 | 25 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis [NCT01848041] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Verification of Performance of Sustained Acoustic Medicine Device Designs Diathermy [NCT05259995] | Phase 1 | 54 participants (Actual) | Interventional | 2022-02-21 | Completed | ||
| The Effects of Tourniquet Use in Total Knee Arthroplasty: A Randomized Controlled Trial [NCT02429713] | 50 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| Descemet Endothelial Thickness Comparison Trial [NCT02373137] | Phase 4 | 38 participants (Actual) | Interventional | 2015-01-22 | Active, not recruiting | ||
| Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea [NCT03352323] | Phase 3 | 50 participants (Actual) | Interventional | 2017-10-18 | Completed | ||
| Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With [NCT00552110] | Phase 2 | 707 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy [NCT01048125] | 2 participants (Actual) | Interventional | 2009-08-31 | Terminated(stopped due to Due to difficulty in recruitment and resource restraints) | |||
| Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening: a Non-inferiority Crossover Randomized Controlled Trial (MyMiROPS Trial) [NCT05043077] | Phase 4 | 83 participants (Actual) | Interventional | 2021-09-07 | Completed | ||
| Evaluating the Acute Glycemic Response to Different Strategies of Breaking Up Sedentary Time [NCT04144920] | 12 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| A Phase 2, Single-Center, Open-Label, Randomized, Parallel-Groups, Dose-Ranging Study to Assess the Efficacy and Safety of Intranasally Administered Kovacaine Mist for Anesthetizing Maxillary Teeth in Pediatric Subjects [NCT01701505] | Phase 2 | 48 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Pre-emptive Epinephrine Nebulization Prior to Nasotracheal Intubation for Mandibular Fracture Fixation Surgeries:Dose it Really Differs? a Randomized Controlled Study [NCT05738564] | Phase 3 | 126 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults [NCT01710787] | Phase 3 | 110 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| ZetrOZ Wearable Ultrasound Clinical Study [NCT02083861] | 93 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Effect of Topical Phenylephrine 2.5% on Episcleral Venous Pressure in Normal Human Eyes [NCT02965924] | 20 participants (Actual) | Interventional | 2016-10-31 | Completed | |||
| The Effect of Phenylephrine Versus Ephedrine on Cerebral Perfusion During Carotid Endarterectomy [NCT01451294] | 40 participants (Anticipated) | Interventional | 2011-11-30 | Not yet recruiting | |||
| Norepinephrine Versus Phenylephrine Infusion for Prophylaxis Against Spinal Induced Hypotension in Elderly Undergoing Hip Arthroplasty Under Spinal Anesthesia: A Randomized Comparative Trial [NCT04195321] | Phase 4 | 62 participants (Actual) | Interventional | 2020-01-01 | Completed | ||
| A Comparison Between Phenylephrine and Norepinephrine Boluses in Prevention of Post-spinal Hypotension During Cesarean Delivery [NCT03015857] | Phase 2 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| A Randomized, Double-Masked, Parallel-Group, Phenylephrine-Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing U [NCT02132312] | Phase 3 | 78 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase I, Open-Label, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intra-anal Application of Topical Oxymetazoline Gel in Healthy Adult Volunteers [NCT03529487] | Phase 1 | 40 participants (Anticipated) | Interventional | 2018-08-20 | Active, not recruiting | ||
| [NCT02132117] | Phase 3 | 445 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| A Phase II, Single-Center, Randomized, Double-Blind, Active-Treatment-Controlled, Parallel-Group Study of the Efficacy of Kovacaine Nasal Spray for Anesthetizing Maxillary Teeth in Healthy Dental Patients [NCT01302483] | Phase 2 | 45 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Middle Ear Pressure Regulation in Health and Disease -- Gas Supply, Demand and Middle Ear Gas Balance -- Specific Aim 2 [NCT01925729] | Phase 1 | 84 participants (Actual) | Interventional | 2013-10-01 | Completed | ||
| A Single-Center, Open-Label, Observer-Masked, Active-Controlled, Phase 2 Study of the Safety, Efficacy and Pharmacokinetics of EYN-1601 in Dilation of the Pupil [NCT02946125] | Phase 2 | 12 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respirator [NCT01576809] | Phase 3 | 51 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Methylene Blue as a Third-line Vasopressor in Septic Shock to Maintain Hemodynamics [NCT04089072] | Phase 2 | 250 participants (Anticipated) | Interventional | 2019-12-01 | Recruiting | ||
| [NCT01813149] | 128 participants (Actual) | Interventional | 2012-08-31 | Terminated(stopped due to Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention. There is no data collected) | |||
| A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis [NCT02436759] | Phase 3 | 140 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma [NCT05527795] | 1,000 participants (Anticipated) | Observational | 2019-01-01 | Recruiting | |||
| A SingleDose Rand, TwoPeriod, Crossover Bioequivalence Study Between a Combination Tablet With Paracetamol, Guaifenesin and Penylephrine HCL (Wrafton Lab Ltd, UK) and Vicks Active SymptoMax Plus, Powder for Oral Solution (Wrafton Lab Ltd, UK) in Healthy A [NCT03213353] | Phase 1 | 72 participants (Actual) | Interventional | 2017-07-03 | Completed | ||
| Optimal Method for Mydriasis in Cataract Surgery [NCT02909140] | 3 participants (Actual) | Interventional | 2016-09-30 | Terminated(stopped due to insufficient patient recruitment) | |||
| Effects of Norepinephrine vs. Phenylephrine on the Graft Blood Flow Measured by Transit Time Flowmetry in Breast Reconstruction With Free Flap Transfer Surgery: a Pilot Study [NCT05049278] | 20 participants (Actual) | Interventional | 2021-09-24 | Completed | |||
| Effect of Target Intraoperative Blood Pressure on the Incidence of Post-operative Cognitive Dysfunction in Patients Aged 75 and Older Undergoing General Anesthesia for Non-cardiac Surgery: an International Multicenter Randomized Controlled Trial [NCT02428062] | Phase 2/Phase 3 | 1,812 participants (Anticipated) | Interventional | 2014-10-31 | Suspended(stopped due to Pending Pilot study results evaluation) | ||
| Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury - A Randomized Control Trial [NCT01731444] | Phase 1 | 24 participants (Anticipated) | Interventional | 2014-12-01 | Recruiting | ||
| Cardiac Index Changes With Ephedrine, Phenylephrine, Ondansetron and Norepinephrine During Spinal Anesthesia for Cesarian Section [NCT03421860] | Phase 4 | 120 participants (Actual) | Interventional | 2017-02-23 | Completed | ||
| A Randomized Controlled Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients [NCT02203630] | Phase 4 | 17 participants (Actual) | Interventional | 2014-08-31 | Terminated(stopped due to Slow enrollment; Lack of support and equipoise) | ||
| A Double Blind Randomized Controlled Trial of Phenylephrine for the Prevention of Spinal Induced Hypotension in Obese Parturients [NCT01481740] | Phase 4 | 178 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Phenylephrine Dose-Finding Study to Minimize Hypotension Due to Spinal Anesthesia for Cesarean Section [NCT00379691] | 50 participants | Interventional | 2006-08-31 | Completed | |||
| Effectiveness of Oxymetazoline Added on Intranasal Steroid in the Treatment of Allergic and Nonallergic Rhinitis With Persistent Nasal Obstruction [NCT01847131] | Phase 4 | 50 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size [NCT02895035] | Phase 4 | 59 participants (Actual) | Interventional | 2016-09-01 | Terminated(stopped due to Data analysis was never performed by sub-investigator) | ||
| Phenylephrine vs. Norepinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Delivery [NCT02354833] | Phase 4 | 85 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain [NCT04829799] | Phase 4 | 0 participants (Actual) | Interventional | 2022-02-28 | Withdrawn(stopped due to Per study team, the study will not proceed) | ||
| A Randomized, Double-Blinded Placebo Control Trial of Nasal Phenylephrine in Infants With Bronchiolitis [NCT00373802] | Phase 2 | 50 participants | Interventional | 2005-01-31 | Completed | ||
| A Randomized, Double-Blind, Single-Center, 5 Way Cross-Over Study to Assess the Effect of Adding Oral Phenylephrine and Oral Sorbitol to Low Dose (1.5 mg) Plain Oral Morphine in Human Volunteers: Analgesia and Side Effect Assessment. [NCT00374881] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery [NCT03228914] | Phase 4 | 20 participants (Actual) | Interventional | 2018-06-14 | Completed | ||
| A Single Dose, Open Label, Randomized Scintigraphic Study to Investigate the Gastrointestinal Behavior of 2 Triple Combination Products (Acetaminophen, Phenylephrine and Dextromethorphan) in Healthy Male Volunteers [NCT03415243] | Phase 1 | 28 participants (Actual) | Interventional | 2018-03-01 | Completed | ||
| Comparison of the Effect of Epinephrine, Norepinephrine and Phenylephrine on Spinal Anesthesia Induced Hypotension [NCT03163914] | Phase 4 | 160 participants (Actual) | Interventional | 2017-07-19 | Completed | ||
| Effectivenes of Phenylefrine in Prevention of Hypotension During Spinal Anesthesia for Cesarean Delivery: a Randomised Controlled Trial [NCT02979405] | Phase 4 | 140 participants (Actual) | Interventional | 2017-01-17 | Completed | ||
| Maternal Microcirculation & SDF Imaging: A Novel Assessment of the Microcirculation During Cesarean Delivery With Spinal Anesthesia and the Impact of Phenylephrine Prophylaxis to Prevent Spinal Anesthesia-induced Hypotension. [NCT02376192] | Phase 4 | 32 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity [NCT04436731] | Early Phase 1 | 104 participants (Anticipated) | Interventional | 2020-12-09 | Recruiting | ||
| Compared Efficacy and Tolerance of Two Vasopressors Used to Treat Preoperative Hypotension During Carotid Surgery. Prospective Randomised Controlled and Single Centre Trial [NCT01794273] | Phase 4 | 80 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Comparison of Pilocarpine, Brimonidine, Oxymetazoline, Hialuronic Acid, Bromfenac Ophthalmic Compound With Pilocarpine and Brimonidine to Improve Uncorrected Visual Acuity in Healthy Presbyopic Individuals [NCT05001243] | Phase 1 | 11 participants (Anticipated) | Interventional | 2021-08-10 | Recruiting | ||
| Three Protocols for Phenylephrine Administration for Prophylaxis Against Post-spinal Hypotension During Cesarean Delivery [NCT03302039] | Phase 4 | 217 participants (Actual) | Interventional | 2017-10-06 | Completed | ||
| Ephedrine Versus Phenylephrine Infusion for Prevention of Spinal Hypotension During Cesarean Section: Effect on Maternal Cardiodynamics and Fetal Circulation: Randomized Double-blind Study [NCT03047109] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Comparison of Intravenous Phenylephrine and Norepinephrine for Treatment of Spinal-induced Hypotension in Caesarian Deliveries [NCT04789005] | Phase 3 | 80 participants (Actual) | Interventional | 2019-11-10 | Completed | ||
| Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia Undergoing Cesarean Section: a Randomized, Controlled Trial [NCT04556357] | 138 participants (Actual) | Interventional | 2020-09-22 | Completed | |||
| Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain:Randomized-Controlled Clinical Trail [NCT02125968] | Phase 4 | 70 participants (Actual) | Interventional | 2014-05-31 | Terminated | ||
| Tourniquet vs. no Tourniquet During High Tibial Osteotomy：A Randomized Controlled Trial [NCT04992533] | 50 participants (Anticipated) | Interventional | 2019-11-30 | Recruiting | |||
| A Prospective, Randomized, Investigator-Blind Study to Compare Three Days of Treatment With Paracetamol (500 mg) / Dimethindene Maleate (1 mg) / Phenylephrine Hydrochloride (10 mg) Tablets Versus Paracetamol 500 mg Alone in the Treatment of Nasal Congesti [NCT01448057] | Phase 3 | 341 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Colloid Co-hydration and Vasoconstrictor Infusion for Prevention of Postspinal Hypotension During Elective Cesarean Section. A Comparative Study [NCT04404946] | 120 participants (Actual) | Interventional | 2020-05-23 | Completed | |||
| Crystalloid Coload Combined With Variable Rate Phenylephrine Infusion for Prevention of Hypotension During Spinal Anesthesia for Elective Cesarean Delivery vs Crystalloid Coload Alone [NCT01378325] | Phase 4 | 80 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| GUARDIAN (NCT04884802) Sub-study Comparing Phenylephrine and Norepinephrine [NCT04934748] | Phase 4 | 6,254 participants (Anticipated) | Interventional | 2021-07-15 | Enrolling by invitation | ||
| "Haemodynamic Stability During Induction of General Anesthesia With Propofol and Remifentanil: A Randomized, Controlled, Double-blind Study Comparing Equipotent Prophylactic Doses of Ephedrine, Phenylephrine, Norepinephrine vs Placebo." [NCT03864094] | Phase 4 | 99 participants (Anticipated) | Interventional | 2022-03-15 | Recruiting | ||
| The Choice of Vasopressor for Treating Hypotension During General Anesthesia: a Pilot Pragmatic Cluster Cross-over Randomized Trial (the VEGA-1 Trial) [NCT04789330] | Phase 4 | 2,000 participants (Actual) | Interventional | 2021-07-01 | Completed | ||
| Hemodynamic Effect of Prophylactic Phenylephrine Versus Lower Limb Compression in Women During Caesarean Section Under Spinal Anaesthesia [NCT01278238] | 120 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Phenylephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia Undergoing Cesarean Section: a Randomized, Placebo-controlled Dose-finding Trial [NCT04576663] | 95 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Pilocarpine, Brimonidine, Oxymetazoline Ophthalmic Compound Safety and Efficacy in Patients With Presbyopia [NCT05006911] | Phase 1 | 11 participants (Anticipated) | Interventional | 2021-08-14 | Recruiting | ||
| A Randomized, Placebo- and Benchmark-controlled, Double-blind Clinical Trial of Anusol Topical Ointment to Evaluate Symptom Relief in Patients With Haemorrhoids [NCT05157711] | Phase 3 | 66 participants (Actual) | Interventional | 2021-11-25 | Completed | ||
| Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery [NCT04602767] | Phase 4 | 260 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| A Single Center, Pilot Study of Induced Hypertension for Minimizing Infarct Progression in Patients With Acute Large-vessel Occlusion Ischemic Stroke Undergoing Endovascular Therapy [NCT04218773] | Early Phase 1 | 40 participants (Anticipated) | Interventional | 2020-09-11 | Enrolling by invitation | ||
| A Randomized, Placebo-Controlled Trial to Evaluate the Effects of Phenylephrine HCl 30 mg Extended-Release Tablets on Nasal Congestion in Subjects With Allergic Rhinitis [NCT01413958] | Phase 3 | 575 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension in Patients Undergoing Caesarean Section: A Randomized Sequential Allocation Dose-finding Study. [NCT05035888] | 80 participants (Actual) | Interventional | 2022-09-05 | Completed | |||
| The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of The Highest Phase 3 Dose Of Kovacaine™ Mist To Healthy Volunteers [NCT01807624] | Phase 2 | 24 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea. A Double Blinded Placebo Controlled, Crossover Prospective Tri [NCT02630121] | Phase 4 | 52 participants (Anticipated) | Interventional | 2023-04-30 | Recruiting | ||
| The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Palpebral Fissure Height, Eye Redness, and Patient-reported Eye Appearance [NCT04831047] | Phase 4 | 114 participants (Actual) | Interventional | 2021-06-08 | Completed | ||
| Long Duration Therapeutic Ultrasound on Tendon Injuries [NCT02340273] | 13 participants (Actual) | Interventional | 2014-12-31 | Terminated | |||
| Efficacy of Tetracaine/Oxymetazoline Nasal Spray for Endodontic Treatment [NCT03502135] | Phase 4 | 0 participants (Actual) | Interventional | 2018-09-30 | Withdrawn(stopped due to study drug not available in time) | ||
| Phase 4 Open Label Study to Determine Pharmacokinetics of Phenylephrine and Pharmacodynamic Effects on BP Via IV Admin of Phenylephrine Hydrochloride Inj in Ped Subjects (≥12 to 16 Years of Age) Undergoing Gen and Neuraxial Anesthesia [NCT02323399] | Phase 4 | 100 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| The Impact of Carbon Monoxide and Altitude on Vascular Function [NCT04928183] | 19 participants (Actual) | Interventional | 2021-06-10 | Completed | |||
| Maternal Haemodynamic Changes After Crystalloid Co-loading and Phenylephrine Versus Phenylephrine Alone During Spinal Anaesthesia for Elective Caesarean Delivery: a Double-blind, Randomised Controlled Trial Using the Non Invasive Cardiac Output Monitor St [NCT04026685] | 66 participants (Actual) | Interventional | 2020-01-09 | Completed | |||
| A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC) [NCT01275105] | Phase 2 | 68 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2) [NCT02673996] | 125 participants (Anticipated) | Observational | 2016-01-31 | Recruiting | |||
| 90% Effective Dose of Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive and Standard Treatment in Preeclamptic Patients During Cesarean Section [NCT06151470] | 80 participants (Anticipated) | Interventional | 2025-07-01 | Not yet recruiting | |||
| Comparison of Two Vasopressor Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Trial [NCT03248791] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-08-20 | Recruiting | ||
| Maternal Cardiac Output Response to Rescue Norepinephrine and Phenylephrine Boluses During Spinal Anesthesia for Caesarean Section in Patients With Severe Preeclampsia: a Randomized, Controlled Trial [NCT05035485] | 32 participants (Anticipated) | Interventional | 2022-09-13 | Recruiting | |||
| A Multicenter, Randomized, Parallel-group, Double-blind, Comparative Trial of the Superiority of Paracetamol 500mg/Fexofenadine 60mg/Phenylephrine 20mg Fixed-dose Combination Versus Placebo in the Symptomatic Treatment of Flu and Cold [NCT05118672] | Phase 3 | 478 participants (Anticipated) | Interventional | 2024-08-30 | Not yet recruiting | ||
| Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS). [NCT03846765] | Phase 4 | 36 participants (Actual) | Interventional | 2019-07-04 | Completed | ||
| A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients [NCT01844830] | Phase 3 | 90 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Placebo for Anesthetizing Maxillary Teeth in Adults [NCT01745380] | Phase 3 | 150 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Evaluation of Patients After Cardiac Surgery: Novel Ultrasound Parameters for Quantification of Renal Perfusion & Analysis of Phenylephrines' Effect on Invasive Haemodynamics and Echocardiographic Measures [NCT04419662] | Phase 4 | 30 participants (Actual) | Interventional | 2020-05-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||